Curriculum Vitae: Darrell Pardi · PDF fileCURRICULUM VITAE . Darrell Spencer Pardi, MD, ......
62
CURRICULUM VITAE Darrell Spencer Pardi, MD, MSc, AGAF, FACG, FACP 1. PRESENT ACADEMIC RANK AND POSITIONS Professor of Medicine, Mayo Clinic College of Medicine, July 2012 Vice Chair, Division of Gastroenterology and Hepatology, June 2013- Associate Dean – Medicine and Pediatrics, Mayo School of Graduate Medical Education, November 2010 - Associate Chair for Fellowship Education, Department of Internal Medicine, 2010 – Consultant, Division of Gastroenterology and Hepatology, Mayo Clinic, 2001 – Chair, GIH Marketing Committee, 2012- Member, AGA Practice Management and Economics Committee, 2015- Member, FDA GI Drug Advisory Committee, 2016-19 2. EDUCATION 1. College: Hamilton College Clinton, New York 13323 Bachelor of Arts with Honors in Biology, June, 1987 Phi Beta Kappa, Summa Cum Laude 2. Medical School: University of Rochester School of Medicine 601 Elmwood Avenue Rochester, New York 14642 Doctor of Medicine with Honor, June 1991 Alpha Omega Alpha 3. Residency: University of Rochester, June 1991 - June 1994 4. Chief Residency: Chief Medical Resident, Instructor in Medicine Rochester General Hospital, June 1994 - June 1995 5. Fellowship: Mayo Graduate School of Medicine, June 1995 - June 1998 Division of Gastroenterology and Hepatology 6. Post Fellowship Mayo Graduate School (b) (6)
Transcript of Curriculum Vitae: Darrell Pardi · PDF fileCURRICULUM VITAE . Darrell Spencer Pardi, MD, ......
CURRICULUM VITAE
Darrell Spencer Pardi, MD, MSc, AGAF, FACG, FACP
1. PRESENT ACADEMIC RANK AND POSITIONS
Professor of Medicine, Mayo Clinic College of Medicine, July 2012
Vice Chair, Division of Gastroenterology and Hepatology, June 2013-
Associate Dean – Medicine and Pediatrics, Mayo School of Graduate Medical
Education, November 2010 -
Associate Chair for Fellowship Education, Department of Internal Medicine, 2010 –
Consultant, Division of Gastroenterology and Hepatology, Mayo Clinic, 2001 –
Chair, GIH Marketing Committee, 2012-
Member, AGA Practice Management and Economics Committee, 2015-
Member, FDA GI Drug Advisory Committee, 2016-19
2. EDUCATION
1. College: Hamilton College Clinton, New York 13323 Bachelor of Arts with Honors in Biology, June, 1987
Phi Beta Kappa, Summa Cum Laude 2. Medical School: University of Rochester School of Medicine
601 Elmwood Avenue Rochester, New York 14642 Doctor of Medicine with Honor, June 1991
Alpha Omega Alpha 3. Residency: University of Rochester, June 1991 - June 1994 4. Chief Residency: Chief Medical Resident, Instructor in Medicine Rochester General Hospital, June 1994 - June 1995 5. Fellowship: Mayo Graduate School of Medicine, June 1995 - June 1998 Division of Gastroenterology and Hepatology 6. Post Fellowship Mayo Graduate School
(b) (6)
Clinical Research Training Program Master of Biomedical Sciences – Clinical and Translational
Science, July 2005 – February 2009 Mayo Quality Fellows Program – Bronze Level Certification,
October 20, 2010
3. BOARD CERTIFICATION
American Board of Internal Medicine, 1994 (inactive) Gastroenterology and Hepatology, 1998 (renewed 2008)
4. MEDICAL LICENSURE
Minnesota #39589 Arizona #27317
5. HONORS/AWARDS
Post Graduate: AGA Future Leaders Program Mentor, third place for project, 2015 ACG Presidential Poster Award, 2015 Annual meeting ACG Category Award (Colon), 2015 Annual meeting ACG Presidential Poster Award, 2014 Annual meeting America’s Top Doctors, Castel Connolly Medical, 2014 DOM Teaching Excellence award, 2013 2012 CTSA Scholarly Opportunity Award (for “high degree of
innovation and significance related to a research topic”) Mayo Fellows’ Association Teacher of the Year Award in
Gastroenterology, 2012 Division of Gastroenterology and Hepatology recognition for excellence
in teaching, 2006-2010, 2012-2013 DOM recognition for excellence in resident education, 2004-2005, 2007-
2013, 2015 DOM Leadership in Education award, 2010
Clinical Trials Research Career Development Award, Miles and Shirley Fiterman Center for Digestive Diseases, 2003-2005
ACG IBD Abstract Award, 2011 AGA Poster of Distinction, 2005 Annual meeting ACG Presidential Poster Award, 2004 Annual meeting ACG/Astra Zeneca Senior Fellow Award, 2003 Annual Meeting
Outstanding Course of the Year by the Mayo School of Continuous Professional Development-Arizona for “Gastroenterology and Hepatology 2010”
AGA Poster of Distinction, 2011 Annual meeting ACG Presidential Poster Award (x2), 2011 Annual Meeting
2011 Best Doctors in Minnesota, Minneapolis/St. Paul Business Journal 2010-2011 Best Doctors (www.bestdoctors.com) AGA Poster of Distinction, 2012 Annual meeting ACG Presidential Poster Award (x2), 2012 Annual Meeting
ACG/Astra Zeneca Senior Fellow Award, 2012 Annual Meeting ACG IBD Abstract Award, 2012 Annual Meeting
Medical School: Doctor of Medicine with Honor Alpha Omega Alpha Letters of Commendation for Outstanding Performance, 1988 and 1989 Bessie Stevens Foundation Scholarship, 1989 Edward T. Mulligan Award, 1991 College: Graduated with Honors in Biology
Summa Cum Laude Phi Beta Kappa Certificate of Distinction for research conducted as a fellow at the
Masonic Medical Research Labs, Utica, New York, 1984 Sigma Xi Certificate of Recognition for excellence in
undergraduate research, 1987 Mary McMaster Hallock Prize for excellence in science, 1987
6. PREVIOUS PROFESSIONAL POSITIONS AND APPOINTMENTS
Associate Chair for Education, Division of Gastroenterology and Hepatology, 2004 - 2012
Associate Professor of Medicine, Mayo Clinic College of Medicine, 2007 – 2012
Program Director, Gastroenterology and Hepatology Fellowship Programs, 2002-2010
Vice Chair, Internal Medicine and Pediatrics Graduate Education Committee, 2009-2010
Chair, Department of Medicine Subcommittee on Subspecialty Training, 2005-2010
Head, Comprehensive GI clinic and interest group, 2005-2010
Assistant Professor of Medicine, Mayo Clinic College of Medicine, 2000 - 2007
Director, GI Bleeding Team (Emergency Endoscopy Service), 2000 - 2003
Senior Associate Consultant, Division of Gastroenterology and Hepatology, Mayo
Clinic, 1998 - 2001
Instructor in Medicine, Mayo Medical School April 1999 – April 2000
Instructor in Medicine, University of Rochester, June 1994 - June 1995
Chief Medical Resident, Rochester General Hospital, June 1994 - June 1995
7. PROFESSIONAL MEMBERSHIPS AND SOCIETIES American Gastroenterological Association
American Gastroenterological Association Fellow, 2008 AGA Academy of Educators, 2012
American College of Gastroenterology Fellow, American College of Gastroenterology, 2005 Fellow, American College of Physicians, 2009 Crohn's and Colitis Foundation of America Association of Subspecialty Professors Minnesota Medical Association Zumbro Valley Medical Association
8. EDUCATIONAL ACTIVITIES A. Curriculum/Course Development
Assisted in development of GI Fellowship Core Curriculum, 1999-2000 Arranged GI lecture series for Critical Care Service, January 2001 Head, Fellowship Curriculum Review Work Group, 2001 Developed and Co-directed Mayo Clinic GI Board Review Course, 2001-2009 Member GIH 2003 CME Conference Planning Committee, July 2001-Feb 2003 Extensive revision of GIH Fellowship Evidence-Based Medicine Journal Club curriculum 2002 Course Director, GIH Fellowship Journal Club, 2003-2004
Developed and Co-directed Regional GI Update CME Course, St. Paul, 2004 Developed and Co-directed Regional GI Update CME Course, Chicago, 2006-
2008 Developed and directed GI CME symposium on Obesity, Mayo Alumni
Meeting, Rochester, MN, 2007 Developed and directed international CME Course, “Gastroenterology &
Hepatology ~ The Year in Review” Digestive Disease Week, San Diego, 2007-2008; Chicago 2008-2009; New Orleans 2009-2010
Course Planning Committee, MSGME Program Directors’ Workshop, Phoenix,
2008-2009
Course Planning Committee, Mayo Clinic Tri-site GI Update course, Phoenix,
2009-2010 Course Planning Committee, Mayo Clinic Tri-site GI Update course, Orlando,
2010-2011 Course Director, Mayo Clinic Tri-site GI Update course, San Diego, 2011-2012 Course Planning Committee, Mayo Clinic Tri-site GI Update course, Phoenix,
2012-2013 Developed and directed Mayo-Dartmouth GI Update course, Manchester, NH,
2015 Young Investigators Research Symposium Advisory Committee, Mayo Fellows’
Association, 2015-2016 AGA Trainee Track co-director (2016) and director (2017)
B. Teaching Activities (Intramural, not counting Divisional conferences/lectures)
Department of Laboratory Medicine and Pathology Grand Rounds, “C.
difficile Infection”, June 2016
PCIM morning conference, “C. difficile infection”, April 2015 GIH Grand Rounds “Pouchitis and Pouch Endoscopy for the non
IBDologist”, Rochester, December 2014 Division of Colorectal Surgery fellow presentation, “Non-IBD Colitidies”,
May 2014, May 2015, Feb 2016 Center for Individualized Medicine, “Differences in the Fecal Microbiome and
Outcomes in C. difficile infection”, December 2013 Center for Individualized Medicine, Microbiome—Promise to Practice
Workshop, “Fecal Microbiome Therapy: An Analysis of Success”, October 2013
Mayo Clinic Internal Medicine Review for Nurse Practitioners, Physician
Assistants and Primary Care Physicians, “Clostridium difficile infection”, Sept 2013
(b) (4)
Practice of Internal Medicine Course, “C. difficile infection: Diagnosis and
Management”, Rochester, May 2013 Internal Medicine Grand Rounds, “Clostridium difficile Infection”, Mayo
Clinic Rochester, May 2013 Mayo Clinic Clinical Reviews 2012, “C. difficile infection”, Rochester,
Oct/Nov 2012 Division of Infectious Diseases Education Retreat, discussion of the “Next
Accreditation System”, August 2012 Division of Cardiology Grand Rounds, “Appropriate use of PPIs in Patients
on Anti-Platelet Agents”, February 2012 Internal Medicine M&M conference, “Severe C. difficile infection”, May
2011 Mayo School of Graduate Medical Education Program Directors’ meeting, “New Duty Hour and Supervision Requirements”, May 2011 Mayo Clinic Division of Colorectal Surgery fellow presentation, “Non-IBD Colitidies II”, May 2011 Mayo Clinic Division of Colorectal Surgery fellow presentation, “Non-IBD Colitidies I”, February 2011 Mayo Rochester IBD interest group, “Treatment of Severe Colitis”, June 2010 Mayo Clinic Practice of Internal Medicine conference, “Inflammatory Bowel Disease: New Concepts and Treatments”, May 2010 Mayo Surgical Pharmacists conference, “C. difficile infection”, Jan 2010 Mayo Colorectal Surgery conference, “C. difficile infection – An Update”, Nov 2009 Internal Medicine Grand Rounds, “Clostridium difficile Infection”, Mayo Clinic Jacksonville, March 2009 Volunteer, Internal Medicine Resident Fellowship Interview Workshop, 2003-2007, 2009
Mayo Clinic Practice of Internal Medicine course, “Lunch with the Professor: Gastroenterology”, May 2007
Mayo Colorectal Surgery morning conference, “Pouchitis”, Jan 2007
Volunteer Assistant, Mayo Medical School Gross Anatomy Laboratory, 2001-2007
Mayo Clinic Practice of Internal Medicine course, “Lunch with the Professor
(GI case discussions)”, May 2006 Mayo Clinic Clinical Reviews course, “GI Clinical Pearls”, Oct and Nov 2005
Mayo Clinic Practice of Internal Medicine Course, “GI Clinical Pearls”, May
2005 Mayo Clinic 2004 GIH Board Review Course "Microscopic Colitis",
Rochester, MN
Annual IBD Management Conference, Rochester MN, May 2004 Case discussions
IM Resident M&M Conference Lecture, "Complicated C. difficile Infection", October 2003
Mayo Clinic 2003 GIH Board Review Course presentations "Gastrointestinal
Infections", "Microscopic Colitis", "C. difficile Infection", “GI Pathology Case studies”, Rochester, MN, September 2003 IM Resident M&M conference, “Management of acute variceal bleeding”, March 2003 Mayo Clinic 2002 GIH Board Review Course, "GI Infections", "Microscopic Colitis", and "C. difficile Infection", Rochester, MN, Sept-October 2002
Mayo Clinic Practice of Internal Medicine Meeting, "Microscopic and C. difficile Colitis: Diagnosis and Management", May 2002 IM Resident Core Conference Lecture, "Gastrointestinal Bleeding", December 2001
Mayo Clinic 2001 GIH Board Review Course presentations "Gastrointestinal Infections", "Microscopic Colitis", and "C. difficile Infection", Rochester, MN, September 2001
Fellows' Quarterly Update, "Obscure GI Bleeding", Rochester Country Club, May 2001 IM Resident Conference, "Motility Disorders", September 2000
E. Honors and Awards for Education
DOM Teaching Excellence award, 2013
Mayo Fellows’ Association Teacher of the Year in Gastroenterology, 2012
Division of Gastroenterology and Hepatology recognition for excellence in
teaching, 2006-2010, 2013
DOM recognition for excellence in resident education, 2004-05, 2007-13, 2015
DOM Leadership in Education award, 2010
MSCPD Outstanding Course Co-director of the Year, 2010
F. Academic Career Development Education-related Development Activities
ACGME annual meeting, 2010-2014, 2016 APDIM annual meeting, 2013 MSGME Program Director’s biennial meetings, 2003- Mayo Faculty Development Program (FEED)
Feedback
Control of Teaching Session - Clinical Supervision
Art of Asking Questions
Case Based Teaching
Diagnosing your Learner
Learning Philosophies
Gastroenterology Training Directors’ Workshop, Orlando, 2009
Stanford Faculty Development Program, Teaching Skills workshop, February 2006
Mayo Medical School Faculty Development Workshop, “Diagnosing the
Learner”, March 2005 Mayo Medical School Faculty Development Program, "Workshop for
Clinical Preceptors: What is Good Clinical Teaching" January 2004
Heterogeneity Meets Homogeneity: Meeting the Challenge of Mentoring Junior Faculty and Trainees, October 2003
Time to Teach Workshop-The Art and Science of Speaking, Mayo Medical
School, March 2001 CME Course Director's Workshop, MSCME, November 2000 Innovations in Education at Mayo, Rochester, MN, September 2000 Rochester General Hospital, Faculty Development Workshop: “Teaching in
the Outpatient Setting”, June 1994
Non-education-related Career Development Activities Leadership Development Training
Mayo Clinic Leadership Challenge Development Program, 2015-2016 The Leadership Prescription, Mayo Office of Leadership and Organization
Development, August 2015 CALD Leadership Forum - Leading Through Influence, May 2009 Mayo All Staff Leadership Course, “Leadership, Change and Institutional
Relationships”, Chaska MN, October 6-8, 2008 Managing Care in the 21st Century Series: -Healthcare Legislation 2003, June 2003
-Managing the Quality and Cost of Healthcare for Local Populations, April 2003 - Academic Centers: Survival in Managed Care, Challenges in the New Millennium, June 2000
Advanced Management Program for Healthcare Executives, University of
Minnesota Executive Development Center, March 2001
Mayo Clinic Leadership Program, January 2002
Mayo Clinic Leadership II Program, February 2003 The Learning Organization, March 2003
Finance at Mayo: A Primer for Physician Leadership, May 2003 2003 Ozmun Lecture in Management, June 2003
IHI 2004 Quality in Healthcare conference
2004 Ozmun Lecture in Management, "Crossing the Quality Chasm: EBM
Meets Evidence-based Management", June 2004
Scholarly Publishing workshop, February 2006 2006 Ozmun Lecture in Management, Leadership: Taking Charge, Colin
Powell May 2006
Mayo Graduate School of Medicine Courses:
HSR 5833 Critical Appraisal of Statistical Methods, 2007 HSR 5535 Introductory Statistical Methods II, 2006 HSR 5511 Managing and Displaying Data, 2006 HSR 5537 Power and Sample Size, 2006 HSR 5530 Introductory Statistical Methods I, 2006 HSR 5832 Advanced Applied Epidemiologic Methods, 2006
HSR 5837 Clinical Trials Design and Conduct, 2006 CR 5747 GI Population Sciences, 2006 Core 6000 Responsible Conduct of Research, 2006 CR 5570 Regulatory Issues in Clinical Research, 2006 HSR 5550 Population Based Research, 2006
HSR 5200 Clinical Epidemiology II, 2005 HSR 5831 Introduction to Clinical Epidemiology, 2005 CR 5550 Applied Enteric Neurosciences, 2005 CR 5600 Clinical Research Protocol Development, 2005
CR 5905 Introduction to Clinical Research, 2005 5000 Introduction to Health Sciences Research, 1998 5200 Design of Clinical Research, 1996 5900 Practical Aspects of Patient-Oriented Research, 1997
9. Scientific Review Activities
Manuscript reviewer for
Annals of Internal Medicine (2016) American Journal of Gastroenterology (2001-2014) Alimentary Pharmacology and Therapeutics (2005-2016) Inflammatory Bowel Diseases (2002-2013) Gastroenterology (2002-2013) Clinical Gastroenterology and Hepatology (2003-2014) Digestive Diseases and Sciences (2005-2009, 2013-14) Gut (2005-2011) Transplant Infectious Disease (2012)
Diseases of the Colon and Rectum (2005-2008) European Journal of Gastroenterology and Hepatology (2008, 2011) Cleveland Clinic Journal of Medicine (2008) Case Reports in Gastroenterology (2008) Inflammatory Bowel Disease Monitor (2008) BioMed Central Gastroenterology (2007-2008) American Journal of Infection Control (2005)
Journal of Clinical Gastroenterology (2004) Journal of Gastroenterology and Hepatology (2004)
Mayo Clinic Proceedings (1999-2003) The Cochrane Hepatobiliary Group (2003) Scandinavian Journal of Gastroenterology (2003, 2011) Journal of Clinical Pathology (2003) Digestion (2003) The American Journal of the Medical Sciences (2000) American Family Physician (2000-03)
Abstract reviewer for AGA Annual Meeting, 2016 Abstract reviewer for AGA Annual Meeting, 2015 Abstract reviewer for AGA Annual Meeting, 2014 Section Editor, Inflammatory Bowel Diseases, 2007-2013 Reviewer of questions for AGA’s GI Online Self-Assessment Module, 2009 Reviewer of Gastroenterology Section of MKSAP 15, 2007 Grant application reviewer for the Dutch Digestive Foundation, 2007 Grant application reviewer for the Broad Medical Research Program, IBD
Grants, The Eli and Edythe L. Broad Foundation, 2003, 2011 Abstract reviewer for ACG Annual Meeting, 2003, 2006 Book Reviewer for Mayo Clinic Proceedings, 2001-2002 Reviewer of questions for the ABIM Gastroenterology Boards, 1999-2002
10. ADMINISTRATIVE RESPONSIBILITIES/COMMITTEE MEMBERSHIP Intramural
Associate Dean – Medicine and Pediatrics, Mayo School of Graduate Medical
Education, 2010-
Interim Associate Dean, Aug – Nov. 2010 Chair, Search committee for Medical Director, Mayo Rochester Multidisciplinary
Simulation Center, 2012 Member, Search committee for Medical Director of Education, Mayo Clinic
Arizona, 2013 Member, Mayo Military Education Group, 2013 Chair, Search committee for Associate Dean, Surgery and Surgical Specialities
Graduate Education Committee, 2014 Chair, Search committee for Designated Institutional Administrator, MSGME,
2014 Member, Search committee for Associate Dean – MOC, MSCPD, 2014 Visiting Resident Task Force, 2014-15 Resident Licensure and Credentialing work group, 2014-5 GMEC funding work group, 2015 I-PASS Advisory Group, 2015- Moonlighting policy work group, 2015 OASES Program Evaluation Steering committee, 2015-
Internal Medicine and Pediatrics (formerly Internal Medicine and Medical Specialties) Graduate Education Committee
Member, 2005 - 2009, Acting Chair as needed Vice Chair, 2009 - 2010 Chair, 2010 - present
Member, GIH Education Committee, 1999 - present -Chair 2002 - 2010 -Fellowship Interview and Selection Committee -"Key Faculty" for GIH Fellowship Program - Head, Fellowship Curriculum Review Work Group, 2001 -Clinical Competency Committee, 2014- -Program Evaluation Committee, 2014- Director, GI Bleeding Team (Emergency Endoscopy Service), 2000-2003
Member, Allied Health Work Group, 2000 Member, GI Division Educational Measures Work Group, 2001 Endoscopy Continuous Improvement Committee, 2001-2002
Gastroenterology and Hepatology Social Committee, 2001-2002 GIH Practice Management Committee, 2001-present Gastroenterology and Hepatology Fellows’ Mentorship Committees, 1999-
Program Director, Gastroenterology and Hepatology Fellowship Training Programs, June 2002-2010
Division of Gastroenterology and Hepatology Vice Chairs/Executive Committee Ad hoc member 2002-2004, full member 2004- Associate Chair for Education, 2004-2012 Division Vice Chair, 2013- Co-directed 2014 strategic planning retreat and oversaw execution of plan Oversaw creation of bariatric endoscopy service line Directed GI bleeding manage-to-reimbursement project Oversaw CRS-GIH endoscopy integration project Oversaw 2016 Specialty Council strategic plan initiative “expanding GIH reach” Division of Gastroenterology and Hepatology Administrative Committee, 2012-2013 Internal Medicine Residency and Clinical Investigator Program applicant interviewer,
2002-present Master’s Faculty privileges in Clinical Research, 2002- Participant, Internal Medicine Residency Interview Workshop, 2003-2007, 2009 Mayo Graduate School of Medicine Resident Travel Task Force, February 2003
Mayo School of Graduate Medical Education, adapted electronic evaluation system for
use in subspecialty training programs, 2005-2006 Head, Comprehensive GI Interest group and clinic, 2005-200
DOM Subcommittee for Subspecialty Training
Member 2002-2015 Chair 2005- 2010 Member, Subspecialty Fellow Professionalism and Communication workshop task force, 2009-2010
Rochester Education Space and Equipment Subcommittee (of the Mayo Rochester
Education Committee), 2006-2013 Education space work group member (block 12 planning), 2011-2012 Mayo Graduate School Clinical Research Training Program course evaluation
committee, 2006 Selection Committee member, DOM Lifetime Achievement Award for Outstanding
Contributions in Medical Education, 2007 Chair, Selection Committee, DOM Teaching Excellence Award, 2007 Helped organize and presented at DOM Education Retreat, Jan 2008
-Presentation: “Answering the Challenge: DOM Fellowships” -Workgroup Leader: “The Education Trajectory” Helped organize DOM Education Retreat, “DOM as a Leader of the Mayo Academic
Enterprise”, organized education-related action items, 2011 7th Biennial MSGME Program Directors’ Workshop Planning Committee, 2008-2009 Chair, Selection Committee, DOM Teaching Excellence Award, 2008 DOM Faculty Recognition and Competence Committee, 2009-2011 Chair, Selection Committee, DOM Distinguished Contributions in Education Award,
2009 Division of GIH Marketing Committee
Member 2010- Chair, 2012-
Department of Medicine Executive Committee and Leadership Committee, 2010-
Member, Hospital Internal Medicine Chair Search committee, 2013 Member, Primary Care Internal Medicine Chair Search committee, 2013 Member, Allergic Diseases Chair Search committee, 2013 Member, Rheumatology Chair Search committee, 2013, 2015 Member, Hematology Chair Search committee, 2014 Member, Nephrology Chair Search committee, 2014
Chair, Selection Committee, DOM Education Research Award, 2011 Department of Medicine Education Council Member, 2010-2015 Chair, 2013-2015
Extramural
AGA Nominating Committee, 2016-2017 AGA Practice Management and Economics Committee, 2015-2018 AGA Future Leaders Program, 2015-2020
Mentor, 2015-16 Co-director, 2016-2018 Director, 2018-2020
Member, FDA GI Drug Advisory Committee, 2015-
AGA Media Speaker’s Bureau, 2015-2016 Minnesota Board of Medical Practice Task Force, 2012
Evaluate the Medical Practice Act and the MN Board of Medical Practice
Represented AGA on GI Milestones/EPA Writing Committee, 2013 AGA Roadmap to the Future of GI Practice Task Force, 2011 AGA Education & Training Committee, 2007-2010
-Represented E&T at AGA Future Trends Committee Consensus Conference on the Future of Gastroenterology Training Programs, Washington, DC, March 2008 -Chair, Ad hoc Training Directors work group, 2008-2009 -Group of Eight work group on the future of GI training, 2009 -Member, Physician Re-entry work group, 2009-2010 -Group of Eight work group to consider re-write of GI core curriculum 2009-2010
AGA Training subcommittee, Chair 2008-2011 One year term; asked to renew twice AGA Program Director’s Caucus steering committee, 2010-2012 AGA Mentor and Advisor Program, 2010-2011 CCFA Educational Advisory Committee, Professional Education Committee 2006-2009 American College of Gastroenterology Publications Committee, 2002-2006
ACG Educational Affairs Committee, 2004-2007
ACG Self-Assessment Test Subcommittee, 2004-2006 ACG Board Recertification Project, 2006
CCFA SE MN Conference Planning Committee, 2004-2005 AGA Manpower and Training Committee work group on restoring the GI fellowship match, 2004
11. INDUSTRY CONSULTING WORK
1) The Biobalance Corporation (E. coli M17 [Probactrix]), 2004-2007 2) Salix Pharmaceuticals (rifaximin), 2005- 3) Larex Corporation/Lonza, (arabinogalactan), 2005-2008 4) Abbott, (talk on treatment of UC and pouchitis), May 2010 5) Pfizer, Inc. (Bosutinib AE Expert panel), 2011
6) Optimer (fidaxomicin, feedback on marketing/slide deck creation), 2011; advisory board meeting, June 2012
7) Santarus (protocol development for Uceris in microscopic colitis), 2013-2014 8) Pfizer, Inc. (Neumega advisory board), 2013 9) Cubist (fidaxomicin advisory board), 2014 10) Seres Health, SER-109 phase 2 trial development Mayo), 2014-2015 11) Seres Therapeutics, SER-109 Advisory board Mayo), October 2015 12) Otsuka America Pharmaceutical, Dec 2015 13) Merck Pharmaceuticals (US C. difficile advisory board), 2016 14) Casdin Capital (CDI/microbiome advising), 2016
12. RESEARCH PRESENTATIONS AT NATIONAL MEETINGS (oral presentations and award winning posters only)
1) DDW San Diego. “Gut Microbiome Signatures at the Time of Primary Clostridium
difficile Infection Predict Recurrence“ (oral), May 2016
2) DDW San Diego. “Outcomes of Fidaxomicin Treatment of Clostridium difficile Infection (AGA Poster of Distinction), May 2016
3) ACG Annual Meeting, Philadelphia, “Predictors of Mortality in Hospitalized Adults With C. difficile Infection” October 2014, (ACG Presidential Poster Award)
4) ACG Annual Meeting, Las Vegas. “Prior Appendectomy is Not Associated with Adverse Outcomes in Clostridium difficile Infection– A Population Based Study”, October 2012 (ACG Presidential Poster Award)
5) ACG Annual Meeting, Las Vegas. “Clinical Predictors of Recurrent Clostridium
difficile Infection”, October 2012 (ACG Presidential Poster Award)
6) ACG Annual Meeting, Las Vegas. “The Epidemiology and Outcomes of Clostridium difficile Infection in Children from 2005-2009: Results from a Nation-wide Survey (oral), October 2012 (ACG/Astra Zeneca Fellow Award).
7) DDW, San Diego. “The Efficacy and Safety of Rifaximin vs. Vancomycin in the
Treatment of Mild to Moderate C. difficile Infection: A Randomized Double-Blind Active Comparator Trial” (Poster of Distinction), 2012
8) ACG Annual Meeting, Washington DC. “Derivation of a Microscopic Colitis Disease
Activity Index” (oral), November 2011 9) ACG Annual Meeting, Washington DC. “C. difficile Infection: An Independent
Predictor for Increased Length of Stay and Mortality amongst hospitalized adults (oral). November 2011
(b) (4)
(b) (4)
10) ACG Annual Meeting, Washington DC. “Predictors of Hospitalization in Community-acquired Clostridium difficile Infection: A Population-based Study” (oral), November 2011
11) ACG Annual Meeting, Washington DC. “An Evaluation of Repeat Polymerase Chain
Reaction Stool Testing for C. difficile Infection”, November 2011. (ACG Presidential Poster Award)
12) ACG Annual Meeting, Washington DC. “Validating Acute Kidney
Injury as a marker of Severity in C. difficile Infection in Hospitalized Adults: Results from a Nation-wide survey”, November 2011 (ACG Presidential Poster Award)
13) British Society of Gastroenterology, Birmingham. “Gastric acid suppression and
outcomes from C. difficile infection: a population-based study” (oral), March 2011 14) DDW, Chicago. “Age is associated with adverse events from biologic therapy in
patients with inflammatory bowel disease” (oral), May 2010 15) ACG Annual Meeting, San Diego. “Comparison of Community acquired and Hospital
acquired Clostridium difficile infection: A population based study” (oral), October 2009 16) DDW, San Diego. “The natural history of microscopic colitis treated with
corticosteroids” (oral), May 2008 17) DDW, Washington, DC. “Pouchitis and Pouch Dysfunction After IPAA for Ulcerative
Colitis or Indeterminate Colitis: a Population-Based Study” (oral), May 2007 18) DDW, Washington, DC. “Musculoskeletal Injury Among Endoscopists: A Controlled
Study” (oral), May 2007 19) ACG Annual Meeting, Las Vegas, NV. “Exposure to Diagnostic Ionizing Radiation in a
Population-Based Cohort of Patients with Inflammatory Bowel Disease” (oral), October 2006
20) ACG Annual Meeting, Honolulu, HI. “Association of INR levels with rates of post-
polypectomy bleeding” (oral), October 2005
21) DDW, Chicago, IL. “Symptomatic Overlap Between Irritable Bowel Syndrome and Microscopic Colitis”, AGA Poster of Distinction, May 2005
22) DDW, Chicago, IL. “Microscopic colitis is not associated with appendectomy or
cholecystectomy”, May 2005
23) ACG Annual meeting, Orlando, Fl. “Collagenous colitis, but not lymphocytic colitis, is associated with cigarette smoking”, October 2004
24) ACG Annual meeting, Orlando, Fl. “Microscopic colitis is not associated with an increased risk of colorectal cancer”, October 2004
25) DDW, New Orleans, LA. “The Epidemiology of Microscopic Colitis: A Population-
Based Study in Olmsted County, MN” (oral), May 2004
26) DDW, New Orleans, LA. “Apoptotic colopathy: New Subtype of Microscopic Colitis or Epiphenomenon?” May 2004
27) DDW, Atlanta, GA. "Treatment Outcomes in Lymphocytic Colitis" May 2001
28) DDW, Atlanta, GA. "Ursodeoxycholic Acid as a Chemopreventive Agent in Patients
with Ulcerative Colitis and Primary Sclerosing Cholangitis" May 2001
29) ACG Annual Meeting, New York, NY. "Gastric Outlet Obstruction: an Unusual Complication of Tuberculosis in Two Brothers" October 2000
30) ACG Annual Meeting, New York, NY. "The use of Montelukast as a steroid-sparing
agent in recurrent eosinophilic gastroenteritis" October 2000
31) DDW, San Diego, CA. "Use of immunomodulators in the treatment of microscopic colitis" May 2000
32) ACG Annual Meeting, Phoenix, AZ. "Loss of Interstitial Cells of Cajal and
Paraneoplastic Dysmotility" October 1999
33) DDW, New Orleans, LA. “Early infection with measles virus is associated with the development of inflammatory bowel disease” May 1998
34) Young Investigators Conference in Digestive Diseases, Santa Monica, CA. “Early
infection with measles virus is associated with the development of IBD” (oral), April 1998.
35) ACG Annual Meeting, Chicago, IL. “Perinatal measles exposure is not invariably
associated with the development of inflammatory bowel disease” November 1997.
36) DDW, Washington, DC. “Acute Major GI Hemorrhage in IBD” May 1997.
37) Young Investigators Conference in Digestive Diseases, San Antonio, TX. “Acute Major GI Hemorrhage in Inflammatory Bowel Disease” (oral), April 1997.
38) ACG Annual Meeting, Seattle, WA. “Pneumatosis coli: a rare finding in C. difficile-
associated pseudomembranous colitis” October 1996.
39) ACG Annual Meeting, Seattle, WA. “Hepatitis-associated aplastic anemia: further evidence for Parvovirus B19 as a causative agent” October 1996.
Mayo Clinic 2014 GIH Board Review Course presentations “IBD Clinical Features”, “IBD Treatment”, Chicago, September 2014
MSGME biannual Program Directors’ workshop, “ACGME Update”, May 2014 DDW 2014, Oral Abstract Session Chair, “Diagnosis and Management of C. difficile”,
Chicago, IL DDW 2014, Oral Abstract Session Chair, “Disease Complications in IBD”, Chicago, IL American College of Physicians Annual Meeting, “Hospital Medicine: From Admission
to Discharge” (diarrhea workup and C. difficile infection), Orlando, April 2014 Mayo Clinic Gastroenterology and Hepatology Update, “C. difficile Infection”, “IBD
Cases” (breakout), Orlando, March 2014 Selected Topics in Internal Medicine, “Cases in Gut Bacteria” and “Breakfast Curbside
the Professor: Gastroenterology”, Hawaii, Feb 2014 University of Minnesota/Mayo Clinic Emerging Infections in Clinical Practice and Public
Health course, “C. difficile infection and FMT”, Minneapolis, Nov 2013 Mayo Clinic 2013 GIH Board Review Course presentations “IBD Clinical Features”,
“IBD Treatment”, Chicago, September 2013 AGA Postgraduate Course, “Autoimmune Enteropathy”, Orlando, May 2013 Mayo Clinic Gastroenterology and Hepatology Update, “Pouchitis and Pouch
Dysfunction”, “Recurrent C. difficile Infection” (breakout), “IBD Case Discussions’ (breakout), Scottsdale, Feb 2013
ACG Western Regional Postgraduate Course, “Microscopic colitis: Beyond Bismuth”
and “C. Difficile Colitis: New Risk Factors and Treatments”, LA, January 2013 AGA-ASGE Clinical Congress, “Microscopic colitis”, San Diego, January 2013 UTMB Conference on Clostridium difficile Infection “Outcomes in Community
Acquired CDI”, Galveston, December 2012 Mayo Clinic 2012 GIH Board Review Course presentations “IBD Clinical Features”,
“IBD Treatment”, “Miscellaneous Disorders”, Chicago, September 2012 AGA Postgraduate course, “Microscopic colitis”, San Diego, May 2012 International Falk Workshop on Microscopic Colitis, “Microscopic colitis: The
American Perspective”, Session moderator “Pathogenesis”, Basel, Switzerland, May 3, 2012
Emirates Gastroenterology & Hepatology Society 7th Emirates Gastroenterology &
Hepatology Conference, “Microscopic colitis” and “C. difficile infection: current concepts”, Dubai, UAE, April 13-15, 2012
Regional CCFA Education Summit, “C. difficile infection”, Bloomington, MN, March
31, 2012 CME web cast, “A call to action: optimal diagnosis and treatment of IBD in the older
adult”, Penn State University, March 2012 ACG 2011, “Fourth Year Fellowships in GI training”, and “Roundtable discussion:
Academics”, Washington, DC, October 2011 Mayo Clinic 2011 GIH Board Review Course presentations “IBD Clinical Features”,
“IBD Treatment”, “Miscellaneous Disorders”, Chicago, September 2011 DDW 2011 Session Moderator, “Endoscopy in IBD”, Chicago, May 2011 DDW 2011 Session chair, “Developing and Teaching a Gastroenterology Curriculum
in Women’s Health Issues”, Chicago, May 2011 GI Training Directors Workshop, "Clinical and Cognitive Competencies", "Scholarly
Competencies", panel discussion, February 2011 Mayo School of Graduate Medical Education leadership retreat, “New Common
Program Requirements”, 2010 Mayo School of Graduate Medical Education Biannual Program Directors’ meeting,
“New Common Program Requirements”, 2010 ACG 2010 “Inflammation and IBS: Do Serologic Tests and Endoscopy Help?”, San
Antonio ACG 2010 “Fellows’ Forum: Academic Career”, San Antonio Mayo Clinic 2010 GIH Board Review Course presentations “IBD Clinical Features”,
“IBD Treatment”, IBD Extraintestinal Manifestations”, “GI Pathology Case studies”, Chicago, August 2010
Minneapolis VA Grand Rounds, “Inflammatory Bowel Disease 2010”, May 2010 CME satellite symposium, “And the diagnosis says…IBS”, New Orleans, May 2010 DDW 2010 Session chair, “Issues Facing GI Fellowship Programs”, New Orleans
Mayo Clinic Gastroenterology and Hepatology 2010 conference, “Pouchitis and other problems after IPAA”, IBD session moderator, Case presentations and panel lead, Feb 2010, Phoenix
ACG 2009, “Persistent Watery Diarrhea: Is it All Microscopic Colitis?”, San Diego (online on
ACG Education Universe http://www.acgcmeuniverse.org/citation.asp?c=49) ACG 2009, “Pouchitis: How to Treat Recurrent and Refractory Disease”. San Diego
(Learning Lunch) Mayo Clinic 2009 GIH Board Review Course presentations "Introduction to the Boards”,
“Miscellaneous Board Review Session”, “GI Pathology Case studies”, Chicago, September 2009
DDW 2009, Meet the Professor lunch, “Medical therapy of Microscopic colitis”, Chicago DDW 2009, Session Chair, “Issues Facing GI Fellowship Programs: a primer for Program
Directors”, Chicago MSGME Program Director’s Workshop, “Best Recruitment Strategies and Evaluating
Applicants”, “Unavoidable Administrative Stuff – MSGME Policies”, “How to Engage this Generation of Learners – small group discussion facilitator”, Phoenix, March 2009
Internal Medicine Grand Rounds, “Clostridium difficile Infection”, Mayo Clinic
Jacksonville, March 2009 Mayo Clinic Winter Meeting, “Microscopic colitis and C. difficile colitis”, “Case
Discussions”, and “Pouchitis and Pouch Dysfunction”, Maui, Mar 2009 Gastroenterology Linked to Endoscopy and Hepatology Meeting, “Pouchitis; Panel
Discussion; Hands-on endoscopy workshop”, Phoenix, February 2009 AGA Clinical Congress, “Microscopic colitis”, Las Vegas, 2009 CCFA National Conference – 7th Annual Advances in IBD, “Microscopic colitis”,
Hollywood, FL, December 2008 CCFA National Conference – 7th Annual Advances in IBD, “Advances in the
management of IBD” session moderator, Hollywood, FL, December 2008 Gastroenterology Grand Rounds, “Epidemiological Studies in Microscopic Colitis”,
Mayo Clinic Rochester, November 2008 Mayo Clinic 2008 GIH Board Review Course presentations "Introduction to the Boards”,
“Miscellaneous Board Review Session”, “GI Pathology Case studies”, Chicago, September 2008
DDW 2008, Oral Abstract Session Chair, “Issues in IBD”, San Diego DDW 2008, “Pursuing A Successful Career in Academia”, San Diego DDW 2008, Meet the Professor lunch, “Microscopic colitis”, San Diego “Optimizing Therapy for Crohn’s Disease”, Mankato, MN, 2008 “Optimizing Therapy for Crohn’s Disease”, LaCrosse, Wisconsin, 2008 Rapid City Medical Group, “Optimizing Therapy for Crohn’s Disease”, Rapid City, SD,
2008 “Optimizing Therapy for Crohn’s Disease”, Bismarck, North Dakota, 2008 Crohn’s and Colitis Foundation National Research and Clinical Conference – 6th Annual
Advances in IBD, “Microscopic colitis: Case studies”, Aventura, FL, December 2007
ACG 2007, “Board Recertification Course - Colon”, Philadelphia Mayo Clinic 2007 GIH Board Review Course presentations "Introduction to the Boards”,
“Miscellaneous Board Review Session”, “GI Pathology Case studies”, Chicago, September 2007
Fargo Gut club, “Biologic Therapy for IBD”, Fargo, North Dakota, August 2007 AGA Nurse Practitioners and Physician Assistants meeting, “Microscopic Colitis”, San
Francisco, August 2007 DDW 2007, Meet the Professor lunch, “Microscopic colitis”, Washington, DC DDW 2007, Oral Abstract Session Chair, “IBD Potpourri”, Washington, DC Sanford School of Medicine, University of South Dakota, Internal Medicine Grand
Rounds, “Update on the Management of Inflammatory Bowel Disease”, April 2007 Avera McKennan Education Center, Sioux Falls, South Dakota, “Biologic Therapy for
IBD”, April 2007 Mayo Clinic Winter Gastroenterology Meeting, “Microscopic colitis”, “Case
Discussions”, and session moderator, Bahamas, Feb 2007 Mayo Clinic Arizona Winter GI Course, "Microscopic Colitis and Other Colitidies" and
“IBD Case Discussions”, Scottsdale AZ, Feb 2007 ACG 2006 Annual Meeting, “Microscopic colitis”, Las Vegas, Oct 2006
ACG 2006 Annual Meeting, “Board Recertification - Colon”, Las Vegas, Oct 2006 Mayo Clinic 2006 GIH Board Review Course presentations "Introduction to the Boards”,
“Miscellaneous Board Review Session”, “GI Pathology Case studies”, Chicago, September 2006
Minneapolis VA Hospital Grand Rounds, “Clostridium difficile Infection”, June 2006 DDW 2006, Meet the Professor lunch, “Pouchitis”, Los Angeles Mayo Clinic Update in Gastroenterology meeting, Chicago, “IBD case discussion”, April 2006 Mayo Clinic 2005 GIH Board Review Course presentations "Gastrointestinal Infections",
"Microscopic Colitis", "C. difficile Infection", “GI Pathology Case studies”, Chicago, September 2005
American College of Physicians Annual Meeting, “GI Clinical Pearls”, San Francisco,
April 2005 14th Annual Advances and Controversies in Clinical Nutrition Meeting, “Nutrition and
IBD" Naples FL, April 2004 Gastroenterology Linked to Endoscopy and Hepatology Meeting, “Microscopic colitis;
Panel Discussion; Case Studies”, Phoenix, February 2004 Canadian SGNA annual meeting, “Management of Non-variceal Upper GI Bleeding”
Toronto, September 2003 Visiting Professor, Rochester General Hospital, “Management of Inflammatory Bowel
Disease”, Rochester, NY, May 2003 Mayo Clinic Scottsdale Case Conference/Research Presentation, "Microscopic colitis:
Clinical Features and Research Opportunities", February 2002 Changing Concepts in the Treatment of Gastrointestinal and Liver Disease, "IBD: Update
on Medical Management", Saint Louis University School of Medicine, April 2001 Gastroenterology and Hepatology for the 21st Century, "Management of Recurrent
Clostridium difficile Infection”, Mayo Foundation, Hawaii, February 2001 Gastroenterology and Hepatology for the 21st Century, Case discussion: "Obscure
Gastrointestinal Bleeding", Mayo Foundation, Hawaii, February 2001
43) Mayo Foundation "Ursodeoxycholic Acid as a Chemopreventive Agent in Patients with Ulcerative Colitis and Primary Sclerosing Cholangitis", IRB #B-1384-00
44) Mayo Foundation "Survey of Lymphocytic Colitis", IRB #2137-99,
45) Mayo Foundation "Pilot Study of 51Cr-EDTA Enemas to Assess Distal Colonic
Permeability", IRB #448-99, March 1999-March 2000,
46) 1997 American College of Gastroenterology Research Award in Clinical Gastroenterology for “Measles Vaccination in Inflammatory Bowel Disease”, July 1997-July 1998,
47) Mayo Foundation, “Measles Vaccination in Inflammatory Bowel Disease”, IRB #213-
97, February 1997-Feb.1998,
48) Mayo Foundation, "Early Measles Infection and Inflammatory Bowel Disease", IRB #212-97,
17. BIBLIOGRAPHY
Peer-reviewed Original Articles (* ):
1) *Cotter TG, Binder M, Harper EP, Smyrk TC, Pardi DS. Optimization of a
Scoring System to Predict Microscopic Colitis in a Cohort of Patients with Chronic Diarrhea. J Clin Gastroenterol 2016;
2)
3)
4)
5)
6) *Cotter TG, Binder M, Harper EP, Smyrk TC, Pardi DS. Validation of a Scoring
System to Predict Microscopic Colitis in a Cohort of Patients with Chronic Diarrhea. Clin Gastro Hep 2016;14:777-8.
(b) (4)
(b) (4)
(b) (4)
(b) (4)
(b) (4)
(b) (4)
(b) (6), (b) (4)
(b) (4)
(b) (4)
(b) (4)
(b) (4)
7) *Khanna S, Pardi DS. Clinical Implications of Antibiotic Impact on Gastrointestinal Microbiota and Clostridium difficile Infection. Exp Rev Gastroenterol Hepatol 2016;
8) Tariq R, Smyrk TC, Pardi DS, Tremaine WJ, Khanna S. New Onset Microscopic colitis in an Ulcerative colitis Patient after Fecal Microbiota Transplantation. Am J Gastroenterol 2016;111:751-2.
9) Lightner AL, Colibaseanu DT, Khanna S, Pardi DS, Dozois EJ, Mathis K Clostridium difficile infection after total proctocolectomy and IPAA for Ulcerative colitis. Colorect Dis 2016;
10) Gupta A, Pardi DS, Baddour L, Khanna S. Outcomes in Children with Clostridium difficile Infection: Results from a Nationwide Survey". Gastroent Rep 2016;1-6.
11) *Khanna S, Pardi DS, Kelly CR, et al. A Novel Microbiome Therapeutic Increases Gut Microbial Diversity and Prevent Recurrent Clostridium difficile Infection. J Infect Dis 2016;
12) Pardi DS. Microscopic colitis (invited review). Am J Gastroenterol 2015;
13) *Dosanjh G, Pardi DS. Chronic unexplained diarrhea. A logical and cost-effective
approach to assessment (invited review). Curr Opin Gastroenterol 2016;32:55-60.
14) Taleban S, Stewart KO, Li DK, Singh P, Pardi DS, et al. Clinical Activity and Quality of Life Indices do not Vary According to Disease Phenotype in Inflammatory Bowel Diseases
15)
16)
17)
18)
19) Orenstein R, Dubberke E, Hardi R, Ray A, Mullane K, Pardi DS, Ramesh MS.
Safety and Durability of the RBX2660 (microbiota suspension) for Recurrent Clostridium difficile Infection: Results of the PUNCH CD Study. Clin Infect Dis 2016;62:596-602.
(b) (4)
(b) (4)
(b) (4)
(b) (4)
20)
21) Pardi DS, Tremaine WJ, Carrasco Labra A. AGA Institute Technical Review on
the Medical Management of Microscopic colitis. Gastroenterology 2016;150:247-74.
22) Bartlett M, Khanna S, Boyce TG, Pardi DS. Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection in Children. J Pediat Gastroenterol Nut 2015;
23) *Singh S, Stroud AM, Holubar SD, Sandborn WJ, Pardi DS. Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis. Cochrane Database Syst Rev. 2015; 11:CD001176.
24)
25) Deepak P, Hanson GJ, Fletcher JG, Tremaine WJ, Pardi DS, et al. Incremental
Diagnostic Yield of Chromoendoscopy and Outcomes in Inflammatory Bowel Disease Patients with History of Dysplasia on White Light Endoscopy. Gastrointest Endosc 2016;83:1005-12.
26) *Khanna S, Gupta A, Baddour LM, Pardi DS. Epidemiology, Outcomes and Predictors of Mortality in Hospitalized Adults with Clostridium difficile infection. Intern Emerg Med 2015;
27) Gerding DN, Meyer T, Lee C, Cohen S, Murthy U, Poirier A, Van Schooneveld T, Pardi DS, et al. Administration of Spores of Non-Toxigenic Clostridium difficile Strain M3 for Prevention of Recurrent C. difficile Infection: A Randomized Clinical Trial. JAMA 2015;313:1719-27.
28) Weber NK, Fletcher JG, Fidler JL, … Pardi DS, et al. Clinical Characteristics and Imaging Features of Small Bowel Adenocarcinomas in Crohns Disease. Abdom Imag 2015;40:1060-7.
29) Singh S, Kullo I, Pardi DS, Loftus EV. Epidemiology, Risk Factors and Management of Cardiovascular Diseases in Patients with Inflammatory Bowel Disease. Nat Rev Gastroenterol Hepatol 2015;12:26-35.
30) Martinez Ugarte ML, Mathis KL, Colibaseanu, D, Khanna S, Pardi DS, Dozois EJ. Clostridium difficile infection after restorative proctocolectomy and IPAA for Ulcerative colitis. Colorec Dis 2016;18:154-7.
(b) (4)
(b) (4)
31) Singh S, Garg SK, Pardi DS, et al. Comparative Efficacy of Biologic Therapy in Patients with Crohn’s Disease: A Systematic Review and Network Meta-analysis. Mayo Clin Proc 2014;89:1621-35.
32) Rose S, Fix OK,….Pardi DS , et al. Entrustable Professional Activities for Gastroenterology Fellowship Training. Gastroenterology 2014;147:233-42.
33) Singh S, Garg SK, Pardi DS, et al. Comparative Efficacy of Pharmacological Interventions in Preventing Relapse of Crohn’s disease after Surgery: A Systematic Review and Network Meta-analysis. Gastroenterology 2014;148:64-76.
34) *Singh S, Pardi DS. Update on Anti-Tumor Necrosis Factor Agents in Crohn’s
Disease. Gastroenterol Clin NA 2014;43:457-78.
35) *Gentile NM, Khanna S, Loftus EV, Smyrk TC, Tremaine W, Harmsen WS, Zinsmeister AR, Kammer P, Pardi DS. The epidemiology of microscopic colitis in Olmsted County from 2002-2010: a population based study. Clin Gastroenterol Hepatol 2014;12:838-42.
36) Pardi DS. Microscopic colitis. Clin Geriatr Med 2014;30:55-65.
37) Gupta A, Patel R, Baddour LM, Pardi DS, Khanna S. Extraintestinal C. difficile infection: Single Center Experience. Mayo Clin Proc 2014;89:1525-36.
38) *Singh S, Loftus EV, Pardi DS. Risk of Cerebrovascular Accidents and Ischemic
Heart Disease in Patients with Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 2013
39) *Weber NK, Bruining DH, Loftus EV Jr, Tremaine WJ, Augustin JJ, Becker BD, Kammer PP, Harmsen WS, Zinsmeister AR, Pardi DS. Comparative outcomes of younger and older hospitalized patients with inflammatory bowel disease treated with corticosteroids. Inflamm Bowel Dis 2013;19:2644-51.
40) *Khanna S, Keddis MT, Noheria A, Baddour LM, Pardi DS. Acute Kidney Injury is an independent marker of severity in Clostridium difficile infection. J Clin Gastroenterol 2013;47:481-4.
41) Eaton J, Smyrk TC, Imam M, Pardi DS, Loftus EV, Owens VL, Talwalkar JT. Fate of Indefinite and Low Grade Dysplasia in Ulcerative Colitis and Primary Sclerosing Cholangitis Before and After Liver Transplantation. Aliment Pharmacol Ther 2013;38:977-87.
42) Shivashankar R, Khanna S, Kammer PP, Harmsen WS, Zinsmeister AR, Baddour
LM, Pardi DS. Clinical Predictors of Recurrent Clostridium difficile Infection in Outpatients. Aliment Pharmacol Ther 2014;40:518-22.
43) Narla NP, Smyrk TC, Pardi DS, Tung J. Clinical Features and Treatment Responses in Pediatric Lymphocytic and Collagenous colitis. J Pediatr Gastroenterol Nutr 2013
44) *Khanna S, Pardi DS. Clostridium difficile infection: management strategies for a difficult disease. Ther Adv Gastroenterol 2014;7:72-86.
45) Rajan E, Iyer PG, Oxentenko AS, Pardi DS, et al. Training in small bowel capsule endoscopy: assessing and defining competency. Gastrointest Endosc 2013
46) Weber NK, Fidler JL, … Pardi DS, et al. Validation of a CT-Derived Method for
Osteoporosis Screening in IBD Patients Undergoing Contrast-Enhanced CT Enterography. Am J Gastroenterol 2014
47) Singh S, Nagpal SJS, Murad MH…Pard DS, et al. Inflammatory Bowel Disease is Associated with an Increased Risk of Melanoma: A Systematic Review and Meta-Analysis. Clin Gastro Hepatol 2014;12:210-8.
48) Katz S, Surawicz CS, Pardi DS. Management of the Elderly Patients with Inflammatory Bowel Disease: Practical Considerations. Inflamm Bow Dis 2013;19:2257-72.
49) Schiller LR, Pardi DS, Spiller R, Semrad CE, Surawicz CM, Giannella RA, Krejs GJ, Farthing MJG, Sellin JH. Chronic Diarrhea: Definition, Classification, Diagnosis. J Gastroenterol Hepatol 2014;29:6-25.
50) McCurdy JD, Loftus EV,… Pardi DS, et al. Cytomegalovirus infection of the
ileoanal pouch. Clinical characteristics and outcomes. Inflam Bow Dis 2013;19:2394-9.
51) *Khanna S, Baddour LM, DiBaise JK, Pardi DS. Appendectomy is not associated with adverse outcomes in C difficile infection: A population based study. Am J Gastroenterol 2013;108:626-7.
52) *Singh S, Sharma P, Loftus EV, Pard DS. Metaanalysis: Serological Markers and the Risk of Acute and Chronic Pouchitis.Aliment Pharmacol Ther 2013;37:867-75.
53) *Gentile NM, Abdalla A, Khanna S..., Pardi DS. Outcomes of patients with microscopic colitis treated with corticosteroids: a population-based study. Am J Gastroenterol 2013;108:256-9.
54)
55) *Abboud R, Pardi DS, Tremaine WJ, Kammer P, Sandborn WJ, Loftus EV.
Symptomatic overlap between microscopic colitis and IBS: a prospective study. Inflamm Bow Dis 2013;19:550-3.
(b) (4)
56) Singh S, Khanna S, Pard DS, Loftus EV, Talwalkar JA. Effect of Ursodeoxycholic Acid use on the risk of colorectal neoplasia: A Systematic Review and Meta-analysis. Inflamm Bow Dis 2013;19:1631-8
57) *Shivashankar R, Khanna S, Kammer PP, Harmsen WS, Zinsmeister AR, Baddour
LM, Pardi DS. Clinical Factors Associated with Development of Severe-Complicated Clostridium difficile Infection. Clin Gastroenterol Hepatol 2013;11:1466-71.
58) *Khanna S, Baddour LM, Huskins WC, Kammer P, Zinsmeister AR, Harmsen WS, Pardi DS. Epidemiology of Clostridium difficile Infection in Children: A Population-Based Study. Clin Infect Dis 2013;56:1401-6.
59) Samuel S, Loftus EV, Bruining DH,… Pardi DS…Sandborn WJ. Validation of the Ulcerative Colitis Colonoscopic Index of Severity and its correlation with disease activity measures. Clin Gastroenterol Hepatol 2012;
60) *Khanna S, Pardi DS. Clostridium difficile infection: new insights into management. Mayo Clin Proc 2012;87:1106-17.
61) *Yen EF, Pardi DS. Non-IBD colitides (eosinophilic, microscopic). Best Prac Res Clin Gastroenterol 2012;26:611-22.
62) *Khanna S, Aronson SL, Kammer, P, Baddour LM, Pardi DS. Gastric acid
suppression and outcomes in C. difficile infection: a population-based study. Mayo Clin Proc 2012;87:636-42
63) Keddis MT, Khanna S, Noheria A, Baddour LM, Pardi DS, Qian Qi. Clostridium difficile Infection in Patients with Chronic Kidney Disease. Mayo Clin Proc 2012;87:1046-53.
64) Pardi DS. Miscellaneous colitides (invited review). Curr Opin Gastroenterol 2011;
65) Kane SV, Horst S, Sandborn WJ, … Pardi DS, et al. Natalizumab for moderate to severe Crohn's disease in clinical practice: The Mayo Clinic Rochester experience. Inflamm Bowel Dis 2012
66) *Gentile N, Murray JA, Pardi DS. Autoimmune Enteropathy. Curr Gastroenterol Rep 2012;14:380-5.
67) *Khanna S, Pardi DS, Aronson SA, Baddour LM, Kammer P. Outcomes in Community-Acquired Clostridium difficile Infection. Aliment Pharmacol Ther 2012;
68) Gerich ME, Pardi DS, Bruining DH, Kammer PP, Becker BD, Tremaine WJ. Tacrolimus salvage in anti-TNF antibody treatment-refractory Crohn’s disease. Inflamm Bow Dis 2012;
69) *Khanna S, Baddour L, Pardi DS. Acute Kidney Injury is an independent marker of severity in C. difficile infection: a nationwide survey. J Clin Gastroenterol 2012;
70) Samuel S, Bruining D, Loftus E…Pardi DS, et al. Validation of the Ulcerative Colitis Colonoscopic Index of Severity and its correlation with disease activity measures. Clin Gastro Hep 2013;11: 49-54.
71) *Khanna S, Pardi DS, Rosenblatt JE, Patel R, Kammer PP, Baddour LM. An Evaluation of Repeat Stool Testing for Clostridium difficile Infection by Polymerase Chain Reaction. J Clin Gastroenterol 2012;46:846-9.
72) Bruining DH, Siddiki HA, Fletcher JG, ... Pardi DS, et al. Benefit of CT enterography in Crohn’s disease: effects on patient management and physician level of confidence. Inflamm Bow Dis 2012;18:219-25.
73) Pardi DS. New ACGME Program Requirements: What You Need to Know (invited review). AGA Perspectives, Dec 2011/Jan 2012.
74) *Khanna S, Pardi DS, Aronson SL, Kammer PP, Orenstein R, St. Sauver JL, Harmsen WS, Zinsmeister AR. The Epidemiology of Community-acquired C. difficile infection: A population-based study. Am J Gastroenterol 2012;in press.
75) Katz S, Pardi DS. Inflammatory Bowel Disease of the Elderly: Frequently Asked
Questions. Am J Gastroenterol 2011;106:1889-97. 76) Thia KT, Loftus EV, Pardi DS, et al. Measurement of endoscopic disease activity
in ulcerative colitis: inter-observer agreement and predictors of severity. Inflamm Bow Dis 2011;17:1257-64.
77) *Yen EF, Pardi DS. Review of the microscopic colitides (invited review). Curr Gastroenterol Rep 2011;13:458-64.
78) *Yen EF, Pardi DS. Microscopic colitis: lymphocytic, collagenous, and ‘mast cell’ colitis. (invited review). Aliment Pharmacol Ther 2011;34:21-32.
79) Eaton JE, Silveira MG, Pardi DS, et al. High Dose Ursodeoxycholic Acid is Associated with the Development of Colorectal Neoplasia in Patients with Ulcerative Colitis and Primary Sclerosing Cholangitis. Am J Gastroenterol 2011;106:1638-45.
80) Thackeray E, Oxentenko AS, Pardi DS, Norby S. Mentorship Programs for Gastroenterology Program Directors: An Unmet Need? J Clin Gastro 2011;
81) Pardi DS, Kelley CP. Microscopic colitis (invited review). Gastroenterology 2011;140:1155-65.
82) Proctor DD, DeCross AJ, Willis CE, Jones TN, Pardi DS. The Match – Five Years Later. Gastroenterology 2011;140:15-8.
83) Sharma P, Saini SD, Bernard L, Rubenstein J, Pardi DS, et al. Knowledge of Hepatocellular Carcinoma Screening Guidelines and Current Practices Among Gastroenterologists. Dig Dis Sci 2011;56:569-77.
84) Swoger JM, Loftus EV, Tremaine WJ, Faubion WA, Pardi DS, et al. Adalimumab for Crohn’s disease in clinical practice at Mayo Clinic: The first 118 patients. Inflamm Bow Dis 2010;16:1912-21.
85) *Hussein S, Pardi DS. Inflammatory Bowel Disease in the Elderly. Drug Aging 2010;27:617-24.
86) DeCross AJ, Proctor D, Pardi DS. Report of the AGA Institute Education and Training Committee Task Force on Physician Reentry. Gastroenterology 2010;139:e17-26.
87) Pardi DS, Miehlke S. Microscopic colitis. Front Gastrointest Res 2010; 26:135-45.
88) *Holubar SD, Cima RR, Sandborn WJ, Pardi DS. Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis. Cochrane Database Syst Rev. 2010; vol. 6 pp. CD001176.
89) Harewood GC, Pardi DS, Hansel S, Maple J, Aslanian H. What do Gastroenterology Trainees Want: Recognition, Remuneration or Recreation? Ir J Med Sci 2010;180:439-44.
90) *Khanna S, Pardi DS. The growing incidence and severity of Clostridium difficile infection in inpatient and outpatient settings. Exp Rev Gastroenterol Hepatol 2010;4:409-16.
91) Malireddy K, Larson D, Sandborn WJ, Loftus EV, Faubion WA, Pardi DS, et al. Recurrence and impact of post operative prophylaxis in laparoscopically treated primary ileocolic Crohn’s Disease. Arch Surg 2010;145:42-7.
92) Friedman LS, Brandt LJ, Elta GH, Fitz JG, Gores GJ, Katz PO, Kuemmerle JF, Pardi DS, Vargo JJ, Stolar MH. Report of the Multisociety Task Force on GI Training. Gastroenterology 2009;137:1839-43 (also published in Am J Gastro 2009;104:2659-63; Gastrointest Endosc 2009;70:823-7; Hepatology 2009;50:1325-9).
93) Pardi DS, D’Haens G, Shen B, Campbell S, Gionchetti P. Clinical guidelines for the management of pouchitis. Inflamm Bow Dis 2009;15:1424-31.
94) Pardi DS. Microscopic colitis. Gastroenterol Hepatol 2009;5:283-8.
95) Guimaraes LS, Fidler JL…Pardi DS, et al. Assessment of Appropriateness of
Indications for CT Enterography in Younger Patients. Inflamm Bow Dis 2009;16:226-32.
96) Afif W, Leighton JA, Hanauer S,…Pardi DS, et al. An Open-Label Study of Adalimumab in Patients with Ulcerative Colitis Including Those with Prior Loss of Response or Intolerance to Infliximab. Inflamm Bow Dis 2009;15:1302-7.
97) Siddiki H, Fidler JL….Pardi DS, et al. Prospective Comparison of State-of-the-Art MR Enterography and CT enterography in Small Bowel Crohn’s Disease. Am J Roentgenol 2009;193:113-21.
98) Hansel SL, Crowell MD, Pardi DS, Bouras EP, DiBase JK. Prevalence and impact of musculoskeletal injury among endoscopists: a controlled pilot study. J Clin Gastroenterol 2009;43:399-404.
99) Shen B, Pardi DS, Bennett, AE, et al. The Efficacy and Tolerability of AST-120 (Spherical Carbon Adsorbent) in Active Pouchitis. Am J Gastroenterol 2009;104:1468-74.
100) Pardi DS, D’Haens G, Shen B, Campbell S, Gionchetti P. Clinical guidelines for the management of pouchitis. Inflamm Bow Dis 2009;15:1424-31.
101) *Peloquin J, Pardi DS, Sandborn WJ, Fletcher JG, et al. Diagnostic Ionizing Radiation Exposure in a Population-based Cohort of Patients with Inflammatory Bowel Disease. Am J Gastroenterol 2008;103:2015-22.
102) *Limsui D, Pardi DS, Smyrk TC, et al. Observer Variability in the Histologic Diagnosis of Microscopic Colitis. Inflamm Bow Dis 2008;15:35-38.
103) Pardi DS, Shen B. Endoscopy in the management of pouchitis after surgery for ulcerative colitis. Endoscopy 2008;40:529-33.
104) Solem CA, Loftus EV, Fletcher JG, et al. Small Bowel Imaging in Crohn's Disease: A Prospective, Blinded, 4-Way Comparison Trial. Gastrointest Endosc 2008;68:255-66.
105) Rubenstein JH, Saini SD, Kuhn L, McMahon L, Sharma P, Pardi DS, Schoenfeld P. Influence of malpractice history on the practice of screening and surveillance for Barrett’s esophagus. Am J Gastroenterol 2008;103:842-9.
106) Akram S, Murray JA, Pardi DS, Alexander GL, Schaffner JA, Russo PA, Abraham SC. Adult Autoimmune Enteropathy: Mayo Clinic Rochester Experience. Clin Gastroenterol Hepatol 2007;5:1282-90.
107) Tremaine WJ, Timmons LJ, Loftus EV, Pardi DS, et al. Age at Onset of
Inflammatory Bowel Disease and the Risk of Surgery for Non-neoplastic Bowel Disease. Aliment Pharmacol Ther 2007;25:1435-41.
108) *Evans PE, Pardi DS. Extraintestinal manifestations of inflammatory bowel disease: clinical implications. Medscape Gen Med 2007;9:55.
109) *Akram S, Pardi DS, Schaffner JA, Smyrk TC. Sclerosing mesenteritis: Clinical features and treatment response. Clin Gastroenterol Hepatol 2007;5:589-96.
110) *Evans PE, Pardi DS. Inflammatory Bowel Disease in the Elderly. Age Aging 2007;3:77-84.
111) Pardi DS, Loftus EV, Smyrk TC, et al. The Epidemiology of Microscopic Colitis: A Population-Based Study in Olmsted County, Minnesota. Gut 2007;56:504-8.
112) Oxentenko AS, Vierkant RA, Pardi DS, et al. Colorectal Cancer Screening Perceptions and Practices: Results from a National Survey of Gastroenterology, Surgery and Radiology Trainees. J Cancer Educa 2007;22:219-26.
113) Oxentenko AS, Goel NK, Pardi DS, et al. Colorectal Cancer Screening Education, Prioritization and Self-Perceived Preparedness among Primary Care Residents: Data from a National Survey. J Cancer Educa 2007;22:208-18.
114) *Limsui D, Pardi DS, Camilleri M, et al. Symptomatic overlap between irritable bowel syndrome and microscopic colitis. Inflamm Bowel Dis 2007;13:175-81.
115) *Oxentenko AS, Pardi DS, Schmoll JA, Gores GJ. Factors predicting initial career choices in Gastroenterology fellows. J Clin Gastroenterol 2007;41:445-50.
116) *Laing AW, Pardi DS, Kammer P, et al. Microscopic colitis is not associated with cholecystectomy or appendectomy. Inflamm Bow Dis 2006;12:708-11.
117) Pardi DS, Sandborn WJ. Review article: Management of pouchitis. Aliment Pharmacol Ther 2006;23:1087-96.
118) *Chopra A, Pardi DS, Loftus EV, et al. Budesonide in the treatment of inflammatory bowel disease: the first year of experience in clinical practice. Inflamm Bow Dis 2006;12:29-32.
119) *Fajardo NR, Pardi DS. Practical approach to microscopic colitis and inflammatory bowel disease (invited article). Pract Gastroenterol 2005;29:19-26.
120) Beaugerie L, Pardi DS. Drug-induced microscopic colitis: proposal for a scoring system and review of the literature. Aliment Pharmacol Thera 2005;22:277-84.
121) Sandborn WJ, Pardi DS. Clinical management of pouchitis. Gastroenterology 2004;127:1809-14.
122) Pardi DS. Microscopic colitis. An update. Inflamm Bowel Dis 2004;10:860-70.
123) *Gonenne J, Pardi DS. Clostridium difficile: An Update. Comprehensive Therapy, 2004;30:134-40.
124) Pardi DS. Concise review for clinicians: Microscopic colitis. Mayo Clin Proc 2003;78:614-7.
125) Kakar S, Pardi DS, Burgart LJ. Colonic ulcers accompanying collagenous colitis: implication of NSAIDs. Am J Gastroenterol 2003,98:1834-7.
126) Smoot R, Gostout CJ, Rajan E, Pardi DS, et al. Is early colonoscopy after admission for acute diverticular bleeding needed? Am J Gastroenterol 2003,98:1996-9.
127) Pardi DS, Loftus EV Jr, Kremers WK, Keach JC, Lindor KD. Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology 2003;124:.889-93.
128) Romero Y, Thistle JT, Longstreth GF, Harmsen WS, Schleck CD, Zinsmeister AR, Pardi, DS, et al. A questionnaire for the assessment of biliary symptoms. Am J Gastroenterol 2003;98:1042-51.
129) Pardi DS, Ramnath VR, Loftus EV Jr, Tremaine WJ, Sandborn WJ. Lymphocytic Colitis: Clinical Features, Treatment, and Outcomes. Am J Gastroenterol 2002;97:2829-33.
130) Pardi DS, Miller SM, Miller DL, Burgart LJ, et al. Paraneoplastic dysmotility: Loss of interstitial cells of Cajal. Am J Gastroenterol 2002;97:1828-33.
131) Pardi DS, Loftus EV Jr, Camilleri M. Treatment of Inflammatory Bowel Disease in the Elderly: An Update. Drugs Aging 2002;19:355-63.
132) Pardi DS, Smyrk TC, Tremaine WJ, Sandborn WJ. Microscopic colitis: A
review. Am J Gastroenterol 2002;97:794-802.
133) *Schwartz DA, Pardi DS, Murray J. Use of montelukast as a steroid-sparing agent for eosinophilic gastroenteritis. Dig Dis Sci 2001;46:1787-90.
134) Viramontes BE, Camilleri M, McKinzie S, Pardi DS, et al. Gender-related
differences in slowing colonic transit by a 5HT3 antagonist in subjects with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol 2001;96:2671-6.
135) Pardi DS, Loftus EV Jr, Tremaine WJ, Sandborn WJ. Treatment of Refractory
Microscopic Colitis with Azathioprine and 6-Mercaptopurine. Gastroenterology 2001;120(6):1482-4.
136) *Yassin S, Young-Fadok TM, Zein NN, Pardi DS. Clostridium difficile-
associated diarrhea and colitis. Mayo Clin Proc 2001;76:725-30. 137) *Chiorean MV, Morford R, Bivins M, Pardi DS. Iliac arteriovenous fistula with
renal insufficiency, ascites, hepatomegaly and abnormal liver test results. Mayo Clin Proc 2001;76:661-3.
138) Pardi DS, Tremaine WJ, Sandborn WJ, et al. Early infection with measles virus is associated with the development of inflammatory bowel disease. Am J Gastroenterol 2000;95(6):1480-5.
139) Pardi DS, Tremaine WJ, Sandborn WJ, Loftus EV, Poland GA, and Melton LJ.
Perinatal measles exposure is not associated with the development of inflammatory bowel disease. Inflam Bow Dis, 1999;5:104-106.
140) Pardi DS, Loftus EV, Tremaine WJ, Sandborn WJ, Alexander GL, Balm RK,
Gostout CJ. Acute major GI hemorrhage in inflammatory bowel disease. Gastrointest Endosc 1999;49:153-7.
141) Pardi DS, Tremaine WJ, Sandborn WJ, McCarthy JT. Renal and urologic
complications of IBD. Am J Gastroenterol 1998;93:504-14.
142) Pardi DS, Tremaine WJ, Rothenberg HJ, Batts KP. Melanosis coli in inflammatory bowel disease. J Clin Gastroenterol 1998;26:167-70.
143) Pardi DS, Romero Y, Mertz LE, Douglas DD. Hepatitis-associated aplastic
anemia and acute Parvovirus B19 infection: a report of two cases and a review of the literature. Am J Gastroenterol 1998;93:468-70.
144) Pardi DS, Tremaine WJ. Inflammatory Bowel Diseases: Keys to diagnosis and
treatment. Consultant 1998;38:87-98. 2) Manuscripts in Preparation:
6) Yen EF, Pardi DS. Microscopic colitis and other miscellaneous
inflammatory and structural disorders of the colon. In: Yamada Textbook of Gastroenterology, 6th edition, DK Podolsky, editor, STMS Signatory Publishers, 2014.
7) Pardi DS, Loftus EV. What is the best medical therapy for IBD in the elderly? Are anti-TNFs safe in this patient population? In: Curbside Consultation in IBD: 49 Clinical Questions, 2nd edition, Rubin D, Friedman S, Farraye F, Eds. Slack, Inc., 2013.
8) Pardi DS. Microscopic colitis. In: Diarrhea, Guandalini S Ed. Springer 2010. 9) Pardi DS. Microscopic colitis. In: Practical Gastroenterology and Hepatology,
Small and Large Intestine and Pancreas, Talley NJ, Ed. Wiley-Blackwell, 2010. 10) Pardi DS, Sandborn WJ. Pouchitis after restorative proctectomy. In: Evidence-
based Gastroenterology & Hepatology, 3rd ed., McDonald JWD, Burroughs A, Fegan B and Fennerty B, Eds. Wiley-Blackwell/BMJ Books, 2010.
11) Pardi DS. How do you treat microscopic colitis. In: Curbside Consultation in
IBD: 49 Clinical Questions, Rubin D, Friedman S, Farraye F, Eds. Slack, Inc., 2009.
12) Loftus CG, Pardi DS. Gastrointestinal Infections, Clostridium Difficile
Associated Disease and Diverticular Disease. In: Mayo Clinic Gastroenterology and Hepatology Board Review, 3rd ed, Hauser SH, Pardi DS, Poterucha JP Eds, Mayo Clinic Scientific Press, 2008.
13) Pardi DS. Inflammatory Bowel Disease and Aging. Special Considerations and
Management. In: The Changing World of Inflammatory Bowel Disease: Impact of Generation, Gender, and Global Trends, Scherl E and Dubinsky M, Eds. Slack, Inc., 2009.
14) Pardi DS. Clinical features, clinical course, and natural history of related
conditions. In: Blackwell Clinical Handbook—Inflammatory Bowel Disease, Loftus EV, Ed. Blackwell Publishing, 2007.
15) Pardi DS, Sandborn WJ. Pouchitis. In: Avances en Patologia Digestiva:
Enfermedad inflammatoria intestinal (Advances in Digestive Pathology: Intestinal Inflammatory Disease), Balanzó J and Ricart E, Eds. ICG Marge, SL and Hospital de la Santa Creu i Sant Pau, Barcelona, 2006.
16) Pardi DS. Microscopic colitis. In: Diarrhea: Evaluation and Treatment,
Zimmerman E, Ed. Humana Press, 2006.
17) Pardi DS. Gastrointestinal infections and Diverticulitis. In: Mayo Clinic Gastroenterology and Hepatology Board Review, 2nd ed, Hauser SH, Pardi DS, Poterucha JP Eds, Mayo Clinic Scientific Press, 2006.
18) Pardi DS. Microscopic colitis and Clostridium difficile-Associated Disease. In:
Mayo Clinic Gastroenterology and Hepatology Board Review, 2nd ed, Hauser SH, Pardi DS, Poterucha JP Eds, Mayo Clinic Scientific Press, 2006.
19) *Evans L, Pardi DS. Nausea and Vomiting. In: Oliveira GHM, Nesbitt GC,
Murphy JG, editors. Mayo Clinic medical manual. Boca Raton: Mayo Clinic Scientific Press, Taylor & Francis Group; 2006.
20) *Cook DA, Pardi DS. Diarrhea. In: Oliveira GHM, Nesbitt GC, Murphy JG,
editors. Mayo Clinic medical manual. Boca Raton: Mayo Clinic Scientific Press, Taylor & Francis Group; 2006.
21) Pardi DS. Microscopic colitis. In: Mayo Clinic Gastroenterology and
Hepatology Board Review, Hauser SH, Pardi DS, Poterucha JP Eds, 2004.
22) Pardi DS. Clostridium difficile-Associated Disease. In: Mayo Clinic Gastroenterology and Hepatology Board Review, Hauser SH, Pardi DS, Poterucha JP Eds, 2004.
23) Pardi DS. Gastrointestinal Infections. In: Mayo Clinic Gastroenterology and
Hepatology Board Review, Hauser SH, Pardi DS, Poterucha JP Eds, 2004.
5) Editorials, Selected Summaries
1) Cotter TG, Pardi DS. Additional Evidence for Drug-induced Microscopic Colitis. Aliment Pharmacol Ther 2016;43:1343-4.
2) Pardi DS. Predicting Microscopic Colitis before Colon Biopsies: A Look into the Crystal Ball? Clin Gastroenterol Hepatol 2015;
3) *Khanna S, Pardi DS. Poor outcomes after Clostridium difficile infection in IBD. Nat Rev Gastroenterol (News and Views section) 2012; .
4) Pardi DS. After budesonide, what next for collagenous colitis? Gut
2009;58:3-4. 5) Pardi DS, Sandborn WJ. Infliximab use and post-operative complications in
ulcerative colitis: causal or confounded association? Dis Colon Rectum 2008;
6) Pardi DS. Recurrent Clostridium difficile infection: an immunodeficiency
state? Clin Gastroenterol Hepatol 2007;5:672-3.
7) Pardi DS. Probiotic Therapy in Patients with Ileal Pouches. The end of the
antibiotic era? Dis Colon Rectum 2007; 8) Pardi DS, Sandborn WJ. Predicting relapse in IBD. What is the role of
biomarkers? Gut 2004;54:321-2.
9) Letters
1) Pardi DS, Shivashankar R, Khanna S, Baddour LM. Clinical predictors of Clostridium difficile infection –advanced age and residential status are important factors for prediction and prevention. Aliment Pharmacol Ther 2015;41:233.
2) *Saffouri G, Khanna S, Estes L, Pardi DS. Outcomes from rectal vancomycin therapy in patients with Clostridium difficile infection. Am J Gastroenterol 2014;109:924-5.
3) *Singh S, Singh H, Loftus EV, Pardi DS. Reply to Theocharidou et al. Clin Gastroenterol Hep 2014;
4) Kane SV,..Pardi D, et al. Effectiveness of split-dose certolizumab pegol for Crohn’s disease: The Mayo Clinic Rochester Experience. Aliment Pharmacol Ther 2013;38:1412.
5) *Khanna S, DiBaise J, Baddour L, Pardi DS. Appendectomy is Not Associated with Adverse Outcomes in Clostridium difficile Infection - A Population Based Study. Am J Gastroenterol 2013;
6) *Khanna S, Pardi DS. “Community-acquired C. difficile infection: An
Emerging Entity”. Clin Infect Dis 2012 7) *Khanna S, Pardi DS. Gastric acid suppression and C. difficile infection: Is
there a causal connection?" Clin Gastro Hep 2012;10:564. 8) Yen EF, Pardi DS. Microscopic colitis and disease associations: authors'
reply. Aliment Pharmacol Ther. 2011;34:820-1. 9) Beaugerie L, Pardi DS. Patients with drug-induced microscopic colitis
should not be included in controlled trials assessing the efficacy of anti-inflammatory drugs in microscopic colitis. Gastroenterology 2009;137:1535-6.
10) *Sweetser SR, Schroeder KW, Pardi DS. Pseudomembranous Colitis
Secondary to Klebsiella oxytoca. Am J Gastroenterol 2009;104:2366-8.
11) Rubenstein JH, Saini SD, Kuhn L, McMahon L, Sharma P, Pardi DS, Schoenfeld P. (reply). Gastroenterology 2008;134:1260.
12) Pardi DS, Loftus EV, Melton LJ, Zinsmeister AR. Epidemiology of Microscopic
Colitis (response). Gut 2007;56:1033.
13) Pardi DS, Limsui D. Utility of Symptom Based Criteria for Evaluating Patients with Chronic Diarrhea. Gastrointest Endosc 2005;62:649.
14) Pardi DS. Should the National GI Fellowship Matching Program Be Restored?
Am J Gastroenterol 2004;
15) Pardi DS. Optimal Acid Suppression Therapy In Critically-Ill Patients. Ann Intern Med 2000;132(11):923-4.
16) Pardi DS, Leighton JA. Re: Pneumatosis intestinalis complicating C. difficile
pseudomembranous colitis. Am J Gastroenterol 2000;95:1107.
7) Non Peer-reviewed Original Articles:
1) Pardi DS. Drug-induced Microscopic colitis (ABIM question monograph), Dec 2014.
2) Pardi DS. Pouchitis In: AskMayoExpert. 2014-10-07. Available from: http://javaprod.mayo.edu/ame/openTopic?collection=1&topicID=4747
3) Pardi DS. Microscopic colitis: the American Perspective. In: Falk Workshop 2012 congress report “Microscopic colitis – Creating Awareness for an Underestimated Disease”, Falk Foundation, Freiburg, Germany.
4) *Khanna S, Pardi DS. Poor Outcomes from C. difficile infection in Patients with
Inflammatory Bowel Disease. Nat Rev Gastroenterol Hepatol 2012; 5) Pardi DS. Sclerosing Mesenteritis. Mayo Clinic Medical Edge, Nov 2011 6) *Khanna S, Pardi DS, Baddour LM, Anderson B. “Management of Clostridium
difficile infection” care process model for ‘Ask Mayo Expert’. January 2011. http://javaprod.mayo.edu/ame/openTopic?page=2&topicID=1297
7) Pardi DS. Microscopic colitis (revised patient education brochure), 2010, 2011 8) Pardi DS. Pouchitis (revised patient education brochure), 2010 9) Pardi DS. PPI therapy as a risk factor for C. difficile infection. ABIM SEP
module question monograph, 2008.
10) Pardi DS. Pouchitis (patient education brochure), 2008. 11) Sexton DJ, Chan SN, Pardi DS, Newman JS. Abdominal pain and weight loss.
Hospitalist 2006. 12) Pardi DS. Microscopic colitis. ACG National Meeting syllabus, October 2006. 13) Gonenne J, Pardi DS. Clostridium difficile associated diarrhea. Department of
Internal Medicine intramural newsletter, March 2005. 14) Pardi DS. Microscopic colitis. Patient Education Brochure. Mayo Foundation.
15) Pardi DS. 20 Common problems in Gastroenterology (Book Review). Mayo
Clin Proc 2003;78:660.
16) Pardi DS. IBD: An update on medical management. Course syllabus, "Changing Concepts in the Treatment of Gastrointestinal and Liver Diseases", St. Louis University, April 2001.
17) Pardi DS. The management of recurrent Clostridium difficile infection. Course
syllabus, "Gastroenterology and Hepatology for the 21st Century", Mayo Foundation, February 2001.
18) Pardi DS. Dyspepsia (Book review). Mayo Clin Proc 2001.
19) Pardi DS. Microscopic colitis. Mayo Clinic Internal Medicine Newsletter,
January 2000.
8) Abstracts:
1) Tariq R, Weatherly R, Kammer P, Pardi DS, Khanna S. Donor Screening Experience for
Fecal Microbiota Transplantation for Patients with Recurrent C. difficile infection. Am J Gastroenterol 2016;
2) 3) Saffouri G, Pardi DS, Kashyap P, Khanna S. Body Mass Index Changes after Fecal
Microbiota Transplantation for recurrent C. difficile infection. Am J Gastroenterol 2016;
4) *Cotter TG, Binder M, …Pardi DS. Development of a Microscopic Colitis Disease Activity Index – A Prospective Cohort Study. Am J Gastroenterol 2016;
5) Garg S, Pardi DS, Khanna S. Clostridium difficile Infection is Associated with Poor
Outcomes in Acute Pancreatitis: Results from the Nationwide Inpatient Sample. Am J Gastroenterol 2016;
6) Khanna S, Vazquez-Baeza Y, González A, et al. Changes in Microbial Ecology after
FMT for recurrent C. difficile Infection Depends on Underlying IBD. Am J Gastroenterol 2016;
7) Garg S, Campbell JP, Anugwom CM, Wadhwa V, Pardi DS, Khanna S. Incidence and predictors of 30-day readmission among patients hospitalized for Clostridium difficile infection
8) Hansel SL, McCurdy J, Barlow JM, et al. Clinical Benefit of Capsule Endoscopy in Crohn’s Disease: Impact on Patient Management and Prevalence of Proximal Small Bowel Involvement. Am J Gastro 2016;
9) Shivashankar R, Tremaine WJ, Harmsen WS, Faubion WA, Kane SV, Pardi DS, Loftus EV. Cumulative Probability and Outcomes of Anti-Tumor Necrosis Factor Use in Patients with Crohn’s Disease: A Population-Based Study. Gastroenterology 2016;
10) Khanna S, Montassier E, Patel R, Kammer PP, Knights D, Pardi DS, Kashyap P. Gut Microbiome Signatures at the time of Primary Clostridium difficile Infection Predict Recurrence Gastroenterology 2016;
11) Meehan AM, Khanna S, Pardi DS. Outcomes from vancomycin taper in patients with recurrent C difficile infection. Gastroenterology 2016;
12) Spiceland C, Saffouri G, Khanna S, Pardi DS. Outcomes of Fidaxomicin Treatment of
Clostridium difficile Infection. Gastroenterology 2016;
13) Tariq R, Singh S, Pardi DS, Khanna S. Gastric acid suppression and recurrent Clostridium difficile infection: A Systematic review and Meta-analysis. Gastroenterology 2016;
14) Gastroenterology 2016;
15) Gastroenterology 2016;
16) Battaglioli EJ, Hale V, Chen J, … Pardi D, et al. Disruptions in gut microbiome in a
subset of patients with diarrhea result in increased susceptibility to Clostridium difficile infection. Keystone annual meeting, 2016.
17) *Dosanjh G, Pardi DS. Predictors of Health Related Quality of Life in Microscopic Colitis
Inflam Bow Dis 2015;22(supplement):S35.
18) *Pestana L, Khanna S, Loftus C, Pardi D. Sclerosing mesenteritis: clinical features, treatment, and outcomes. Am J Gastroenterol. 2015 Oct; 110:S1010. 2015 ACG Presidential Poster Award
19) Gara N, Crespo J, Smyrk TC, Pardi D. Granulomatous microscopic colitis due to
allopurinol. Am J Gastroenterol 2015;110:S160.
20) Pestana L, Pardi D, Khanna S. Crohn's disease, malignant melanoma, and Churg-Strauss syndrome: a treatment dilemma. Am J Gastroenterol. 2015 Oct; 110:S307.
21) *Khanna S, Montassier E, …, Pardi D, Kashyap P. Gut microbiota changes as
predictors of treatment failure in primary clostridium difficile infection. Am J Gastroenterol 2015;110:S578. (oral presentation; 2015 ACG Category Award [Colon])
22) Knanna S, Weatherly R, Kammer P, Pardi D. Management and outcomes of
patients with failed fecal microbiota transplantation for recurrent clostridium difficile infection. Am J Gastroenterol. 2015 Oct; 110:S580.
23) Saffouri G, Weber N, Singh S, Pardi DS, et al. Screening for Bone Health in Patients with
IBD: A Q.I. Project through Point-of-Care Informational Patient Handouts. Am J Gastro 2015;110:S821.
24) Lombardo MJ, Vulic M, Cook DN, Henn MR, Kraft CS, Khanna S, Pardi D, Hohmann EL.
Vancomycin-resistant enterococcal titers diminish among patients with recurrent Clostridium difficile infection after administration of SER-109, a novel microbiome agent. IDSA Week 2015
25) Roda G, Torres J, Hu J, Hao K, Chen A, Harpaz N, Petras R, Pardi DS, et al. Genome-wide
association identifies multiple collagenous colitis susceptibility loci. J Crohns Colitis 2015;9 suppl 1:S70.
26) Alnahhas M, Wadhwa A, Khanna S, Kashyap P, Pardi DS, Dierkhising R,Grover M. Epidemiology of post infectious irritable bowel syndrome following Clostridium difficile infection. UEGW 2015 (oral presentation)
27) Hale V, J. Chen, V. Redkal, B. Schmidt, S. Khanna, P. Jeraldo, C.D. Enriquez-Sarano, Pardi
DS, et al. A subset of patients with diarrhea has an altered gut microbiota similar to C. difficile infection. UEGW 2015 (oral presentation; travel award)
28) Rodríguez-Hernández MJ, Khanna S, Pardi D. Outcomes of Clostridium difficile infections
treatments. IDSA guidelines adherence. XIX Conference Spanish Society of Infectious Diseases and Clinical Microbiology, May 2015.
29) Roda G, Torres J, Hu J, Hao K, Z Zhang, Chen A, Petras R, Pardi DS, et al. Genome-wide
association identifies multiple collagenous colitis susceptibility loci. Gastroenterology 2015;148:S-875.
30) *Gentile NM, Khanna S, Loftus EV, Tremaine WJ, Kammer PP, Pardi DS. Outcomes of
Patients with Microscopic Colitis Treated with Bismuth Subsalicylate. Gastroenterology 2015;148:S-483.
31) Khanna S, Weatherly R, Kammer P, Loftus EV, Pardi DS. Long-Term Follow-Up after
Fecal Microbiota Transplantation for C. difficile Infection in IBD Patients. Gastroenterology 2015;148:S-726.
32) *Hanada Y, Khanna S, Loftus EV, Raffals LE, Pardi DS. Inflammatory Bowel Disease
Flares Associated with Non-Clostridium difficile Bacterial Infections. Gastroenterology 2015;148:S-255.
33) *Spiceland C, Gentile NM, Khanna S, Pardi DS. Concomitant Celiac Disease Does not
Modify the Response Treatment with Bismuth Subsalicylate (BSS) in Patients with Microscopic Colitis. Gastroenterology 2015;148:S-284.
34) *Dosanjh G, Tremaine WJ, Loftus EV, Kammer PP, Harmsen WS, Pardi DS. Quality of
Life in Lymphocytic and Collagenous Colitis. Gastroenterology 2015;148:S-482.
35) Rodriguez Hernandez MJ, Pardi DS, Khanna S. A comparison of community and hospital-acquired Clostridium difficile infection: a population-based cohort study. ESCMID meeting, April 2015.
36) Roda G, Torres J, Hu J, Hao K, Chen A, Harpaz N, Petras R, Pardi DS, et al. Genome-wide
association identifies multiple collagenous colitis susceptibility loci. Inflamm Bow Dis 2014;20:S10.
37) *Spiceland C, Khanna S, Pardi DS. Outcomes of fidaxomicin treatment of Clostridium
difficile infection. Am J Gastro 2014;109:S196.
38) *Khanna S, Pardi DS. Predictors of Mortality in Hospitalized Adults With C. difficile Infection. Am J Gastro 2014;109:S678.
39) Singh S, Garg SK, Pardi D, Wang Z, Murad M, Loftus E. Comparative efficacy of
pharmacological interventions for postoperative prophylaxis after surgical resection in Crohn's disease: a systematic review and network meta-analysis. Am J Gastroenterol 2014; 109:S484-5.
40) *Pestana L, Khanna S, Pardi DS. Treatment outcomes from pentoxifylline in sclerosing
mesenteritis. Am J Gastro 2014;109:S122.
41) Gupta A, Patel R, Baddour LM, Pardi DS, Khanna S. Extraintestinal C. difficile infection: Single Center Experience. IDSA Annual Meeting 2014
42) Batista D, Yadav S, Harmsen WS, Pardi DS, et al. Ustekinumab Treatment for Crohn’s
Disease in Clinical Practice: Experience at a Tertiary Medical Center. Gastroenterology 2014;146:A-711.
43) *Saffouri GB, Khanna S, Pardi DS. Outcomes from vancomycin administration per rectum
after colectomy for Clostridium difficile infection. Gastroenterology 2014;146:A-383.
44) Hanson GJ, Deepak P, Fletcher JG, Tremaine WJ, Pardi DS, et al. Diagnostic Yield of Chromoendoscopy and Outcomes in IBD Patients with History of Dysplasia. Gastroenterology 2014;146:A-1334.
45) Vayu Maini Redkal, Mhd Firas Alnahhas, …, Pardi DS, et al. Chronic diarrhea in subset of
patients with IBD and IBS is associated with altered microbiota. Gastroenterology 2014;146:A-111.
46) Weber NK, Smyrk TC, Bruining DH, Fletcher JG, Fidler JL, Pardi DS, Loftus EV.
Histologic Features of Small Bowel Adenocarcinomas in Crohn’s Disease. Advances in IBD meeting, 2013.
47) *Khanna S, Kashyap PC, Rainey JF, Kammer P, Pardi DS. Outcomes from FMT in Adults
with C. difficile infection and IBD. Am J Gastroenterol 2013;108:S508
48) *Khanna S, Mrazek M, Kammer P, Patel R, Pardi DS. Kinetics of polymerase chain
reaction testing in patients with C. difficile infection. Am J Gastroenterol 2013;108:S175
49) *Singh S, Singh H, Loftus EV, Pardi DS. Risk of Cerebrovascular Accidents and Ischemic
Heart Disease in Patients with IBD: A Systematic Review and Meta-analysis. Am J
Gastroenterol 2013;108:S513
50) *Saffouri G, Khanna S, Pardi DS. Outcomes from rectal vancomycin therapy in patients
with severe-complicated Clostridium difficile infection. Am J Gastroenterol 2013;108:S175
51) Weber N, Pardi DS, Bruining DH. Intestinal Wall Remodeling on CT Enterography May
Not Predict Improved Bone Health. Am J Gastroenterol 2013;108:S518
52) *Khanna S, Pardi DS. Trends in C. difficile: Incidence and Costs - The Nationwide
Inpatient Sample. IDSA annual meeting, 2013.
53) Neis B, Kane S,.....Pardi DS, et al. Effectiveness of Split Dose Certolizumab Pegol for the Treatment of Crohn’s Disease: Experience at a Tertiary Care Center. Gastroenterology 2013;
54) Singh S, Pardi D, Inflammatory Bowel Disease is Associated with an Increased Risk of Melanoma: A Systematic Review and Meta-Analysis. Gastroenterology 2013;
55) Matthis K, Khanna S, Pardi DS, et al. Is Concomitant C. difficile infection and IBD
associated with poor outcomes following colectomy? 2013 ASCRS Annual Meeting.
56) *Shivashankar R, Khanna S, Kammer P, Harmsen W, Zinsmeister A, Baddour L, Pardi DS. Leukocyte Count and Serum Creatinine as Predictors of Severe-Complicated Clostridium difficile Infection in Different Age Groups. Gastroenterology 2013;
57) *Khanna S, Kamath PS, Pardi DS. C. difficile infection related Outcomes in Hospitalized Adults
with Liver Cirrhosis. Gastroenterology 2013;
58) *Gentile NM, Khanna S, Kammer P, Tremaine WJ, Loftus EV, Pardi DS. Outcomes of Microscopic Colitis and Smoking: A Population-based Study. Gastroenterology 2013;S439.
59) *Warsame R, Shivashankar R, Pardi DS. Suicide Attempt From Super-Warfarin Poisoning.
ACP 2013 national meeting. 60) *Singh S, Sharma PK, Loftus EV, Pardi DS. Effect of Antineutrophil Cytoplasmic Antibodies on
the Risk of Acute and Chronic Pouchitis: A Systematic Review and Meta-Analysis. Inflamm Bow Dis 2012;18:SS48-49 2012. Best Overall Poster
61) Singh S, Khanna S, Pardi DS, Loftus EV, Talwalkar JA. "Ursodeoxycholic Acid and Risk of
Colorectal Neoplasia in Patients with Primary Sclerosing Cholangitis and Inflammatory Bowel Disease: A Meta-Analysis." Inflamm Bow Dis 2012;18:S29-30.
62) Weber NK, Fletcher JG, Fidler JL, Barlow JM, Pruthi S, Loftus EV, Pardi DS, Smyrk TC,
Becker BD, Bruining DH. Clinical Characteristics and Imaging Features of Small Bowel Adenocarcinomas in Crohn’s Disease. Inflamm Bow Dis 2012;18:S63-64.
63) Eaton J, Smyrk TC, Imam M, Pardi DS, Loftus EV, Owens VL, Talwalkar JT. Fate of Indefinite
and Low Grade Dysplasia in Ulcerative Colitis & Primary Sclerosing Cholangitis Colitis Before & After Transplant. Hepatology. 2012 Oct; 56:1139A.
64) Eaton J, Smyrk TC, Imam M, Pardi DS, Loftus EV, Owens VL, Talwalkar JT. Predictors of
Colorectal Neoplasia Outcomes in Indefinite and Low Grade Dysplasia in Patients with Primary Sclerosing Cholangitis and Ulcerative Colitis. Am J Gastro 2012;107:S618 (ACG IBD Research Award).
65) *Khanna S, Baddour LM, Faubion WA, Pardi DS. The Epidemiology and Outcomes of Clostridium difficile Infection in Children from 2005-2009: Results from a Nation-wide Survey (ACG/AstraZeneca Fellow Award). Am J Gastro 2012;107:S210.
66) *Gentile NM, Khanna S, Smyrk TC, Kammer PP, Pardi DS. The association b/n microscopic
colitis and celiac disease: A Population-based Study. Am J Gastro 2012;107:S644-5.
67) *Khanna S, Baddour LM, Pardi DS. Prior Appendectomy is Not Associated with Adverse Outcomes in Clostridium difficile Infection– A Population Based Study (Presidential Poster). Am J Gastro 2012;107:S204.
68) *Shivashankar R, Khanna S, Kammer PP, Harmsen WS, Zinsmeister AR, Baddour LM, Pardi
DS. Clinical Predictors of Recurrent Clostridium difficile Infection in Community Acquired Infection (Presidential Poster). Am J Gastro 2012;107:S213
69) *Khanna S, Singh S, Pardi DS. Clinical features and outcomes in hospitalized patients with sclerosing mesenteritis. Am J Gastro 2012;107:S124.
70) *Khanna S, Singh S, Pardi DS. Gastric Acid Suppression and Recurrent Clostridium difficile
infection: A Systematic review and Meta-analysis. Am J Gastro 2012;107:S571-2.
71) Narla N, Smyrk T, Pardi D, Tung J. Clinical Features and Treatment Responses in Pediatric Lymphocytic and Collagenous colitis. Am J Gastro 2012;107:S618.
72) *Khanna S, Baddour LM, Huskins WC…Pardi DS. The Epidemiology of CDI in Children: a
population-based study. North American Conference of GI fellows, 2012. 73) Keddis MT, Khanna S, Baddour LM, Pardi DS, Qian Q. The Impact of Chronic Kidney Disease
on Clostridium difficile Infection-Associated Outcomes. Am J Kidney Dis 2012;59:A46. 74) *Khanna S, Baddour LM, Huskins WC…Pardi DS. The Epidemiology of CDI in Children: a
population-based study. Gastroenterology 2012;
75) *Khanna S, Loftus EV, Baddour LM, Pardi DS. Incidence and Outcomes from C. difficile Infection in Hospitalized Adults with IBD. Gastroenterology 2012;
76) *Gentile NM, Pardi DS, Khanna S, et al. The epidemiology of microscopic colitis: a population-
based update. Gastroenterology 2012;S571. 77) Shivashankar R, Oxentenko AS, Pardi DS. Readmission Rates in Patients with Inflammatory
Bowel Disease Following an Admission for an Acute Flare of Disease. Gastroenterology 2012;Sa 1292.
78) Pardi DS, .The Efficacy and Safety of Rifaximin vs. Vancomycin in the Treatment of Mild to
Moderate C. difficile Infection: A Randomized Double-Blind Active Comparator Trial (Poster of Distinction). Gastroenterology 2012;Mo1116.
79) Tremaine WJ, Faubion WA, Pardi DS, et al. Upper Gastrointestinal Tract Involvement in
Crohn’s Disease Requiring Anti-TNF Therapy: Clinical Characteristics. Gastroenterology 2012;Tu1225.
80) *Gentile NM, Abdalla AA, Khanna S, et al. Clinical Features and Outcomes of Patients with
Microscopic Colitis Treated with Corticosteroids. Gastroenterology 2012;S447. 81) *Khanna S, Baddour LM, Pardi DS. Epidemiology of Clostridium difficile infection in
hospitalized adults in the US. Indian Society of Gastroenterology 2011;
82) *Khanna S, Baddour LM, Pardi DS. Clostridium difficile Infection: An Independent Predictor for Increased Length of Stay and Mortality in hospitalized adults. Am J Gastroenterol 2011;106:S405.
83) Pardi DS, Abboud R, McNally M, Tremaine W, Sandborn W, Kammer P, Harmsen WS,
Zinsmeister A, Loftus E. Derivation of a Microscopic Colitis Disease Activity Index. Am J Gastroenterol 2011;106:S492.
84) *Shivashankar R, Khanna S, Kammer PP, Harmsen WS, Zinsmeister AR, Baddour LM, Pardi
DS. Clinical Predictors of Severe Complicated Clostridium difficile Infection. Am J Gastroenterol 2011;106:S162.
85) Tung J, Enders FT, Jeavons E, Faubion WA, Kane SV, Tremaine WJ, Pardi DS, Bruining
DH, Loftus EV. Infliximab for Ulcerative Colitis in Clinical Practice. Am J Gastroenterol 2011;106:S445.
86) *Gathaiya N, Catania J, Loftus E, Sandborn W, Tremaine W, Baddour L, Kammer P,
Harmsen S, Zinsmeister A, Limper A, Pardi D. Low risk of Pneumocytis jirovecii pneumonia in Patients with IBD Receiving Chronic Corticosteroid therapy does not Justify Prophylaxis –A Population Based Study. Am J Gastroenterol 2011;106:S486.
87) *Khanna S, Kammer P, Baddour LM, Pardi DS. An Evaluation of Repeat Polymerase
Chain Reaction Stool Testing for Clostridium difficile Infection (ACG Presidential Poster). Am J Gastroenterol 2011;106:S145.
88) *Khanna S, Aronson SL, Kammer P, Baddour LM, Pardi DS. Predictors of Hospitalization
in Community-acquired Clostridium difficile Infection: A Population-based Study. Am J Gastroenterol 2011;106:S145.
89) *Khanna S, Keddis M, Baddour LM, Pardi DS. Validating Acute Kidney Injury as a
marker of Severity in Clostridium difficile Infection in Hospitalized Adults: Results from a Nation-wide survey. Am J Gastroenterol 2011;106:S147.
90) *Singhania R, Pardi DS, Pouchitis and other Pouch Dysfunction Syndromes after Ileal
Pouch-Anal Anastomosis for Ulcerative Colitis or Indeterminate Colitis: a Population-Based Study (ACG IBD Abstract Award). Am J Gastroenterol 2011;106:S460.
91) *Abboud R, Pardi DS, Tremaine W, Sandborn W, Loftus E. The association of serologic
inflammatory markers with microscopic colitis. Am J Gastroenterol 2011;106:S164-5.
92) *Khanna S, Baddour LM, Pardi DS. Epidemiology of Clostridium difficile Infection in Hospitalized Adults in the United States. Indian Society of Gastroenterology Annual Meeting, 2011.
93) Keddis MT, Khanna S, Qian Q, Baddour LM, Pardi DS. Clinical Outcomes of Clostridium
difficile Infection in Patients with Chronic Kidney Disease. ASN 2011
94) *Khanna S, Baddour LM, Pardi DS. Nation-wide Survey Outcomes in Adults with Clostridium difficile Infection for 2005-2009. 49th annual IDSA meeting, 2011
95) *Khanna S, Aronson SL, Kammer PP, Pardi DS. Gastric acid suppression and outcomes
from C. difficile infection: a population-based study. (BSG11-ABS-1392), British Society of Gastroenterology (oral), Gut 2011;60(suppl 1):A6-7.
96) Rao A, Camilleri M, Burton D, Eckert D, Pardi DS, et al. Comparison of Small Bowel and
Colonic Mucosal Permeability in Ulcerative/Microscopic Colitis, Irritable Bowel Syndrome-Diarrhea, and Healthy Controls by Urinary Saccharide Excretion Measurements. Gastroenterology 2011
97) Samuel S, Bruining D, Loftus E…Pardi DS, et al. Validation of the ulcerative colitis
endoscopic index of severity (UCEIS) and its correlation with clinical indices and laboratory measures of disease activity. Gastroenterology 2011
98) Rajan E, Ganapathy P, …Pardi DS, et al. Teaching and Assessing Competence in Small
Bowel Capsule Endoscopy During Gastroenterology Fellowship. Gastroenterology 2011
99) Kane S, Loftus EV, Faubion WA, Tremaine WJ, Pardi DS, et al. Limited Clinical Utility of a Self-Administered Tool for Predicting Adherence Behavior in IBD. Gastroenterology 2011
100) Tremaine WJ, Timmons LJ, Bruining DH, Faubion WA, Pardi DS, et al. The (Mitigating) Effects of Angiotensin Inhibitors and Blockers on the Course of Crohn’s Disease: A Population Based Study. Gastroenterology 2011
101) Thackeray E, Oxentenko AS, Pardi DS, Norby S. Mentorship Programs for
Gastroenterology Program Directors: An Unmet Need? (Poster of Distinction) Gastroenterology 2011;
102) *Abboud RF, Pardi DS, Tremaine WJ, Kammer PP, Loftus EV. Symptomatic Overlap
between Irritable Bowel Syndrome and Microscopic Colitis: a Prospective Study. Gastroenterology 2011
103) *Grover M, Aggarwal G, Samuel S, Pardi DS. A Case of Protein Losing enteropathy:
Inflammatory Bowel Disease, Celiac Disease, or something else? Am J Gastro 2010;105 (suppl 1):919
104) *Kaufman L, Loftus E, Sandborn W, Kammer P, Pardi DS. Osteoporosis Screening in a
Tertiary Referral Inflammatory Bowel Disease Clinic. Am J Gastro 2010;105 (suppl 1):1294 (S476)
105) Gerich ME, Tremaine WJ, Pardi DS, Bruining DH, Kammer PP, Becker BD. Higher
Tacrolimus Trough Levels Are Associated with Fewer Surgical Resections in Crohn’s Disease Refractory to Anti-TNFα Therapy. Am J Gastro 2010;105 (suppl 1):1211
106) *Khanna S, Pardi DS. Hemolysis as the clue to the diagnosis of abdominal pain
(hypertriglyceridemic pancreatitis). ACP National meeting, Toronto, 2010.
107) *Khanna S, Aronson SL, Kammer PP, Orenstein R, Pardi DS. Clostridium difficile infection in the elderly: A Population-based study. IDSA Annual meeting, Vancouver, 2010. (discussed in “First Report” section of Clinical Geriatrics, 2011)
108) *Bhushan A, Pardi DS, Loftus EV, et al. Age is (not) associated with adverse events from
biologic therapy in patients with IBD. DDW 2010 (oral).
109) Harewood G, Pardi DS, Hansel SL, Corr A, Aslanian H, John T. Maple JT. What Do Gastroenterology Trainees Want: Recognition, Remuneration or Recreation? DDW 2010.
110) *Khanna S, Aronson SL, Kammer PP, Pardi DS, Treatment of Community acquired
Clostridium difficile Infection in adults. Alumni Association meeting of AIIMS in America, Boston, Aug 2009
111) *Khanna S, Pardi DS. Hemolysis as the clue to the diagnosis of abdominal pain
(hypertriglyceridemic pancreatitis). MN ACP meeting, 2009
112) *Bhushan A, Pardi DS, Loftus EV, et al. The Safety Profile of Biologic Therapy in Older IBD Patients – a Pilot Study. Am J Gastro 2009;104(suppl 3):S464.
113) *Khanna S, Aronson SL, Kammer PP, Orenstein R, Pardi DS. Clostridium difficile
Infection in children: A Community-based Epidemiological Study. Am J Gastro 2009;104(suppl 3):S544.
114) *Khanna S, Aronson SL, Kammer PP, Orenstein R, Pardi DS. Comparison of Community
acquired and Hospital acquired Clostridium difficile infection: A population based study. Am J Gastro 2009;104(suppl 3):S183.
115) Neuman DA, Pardi DS, Murray JA. Clinical Characteristics of Patients with Concurrent
Celiac Disease and Microscopic Colitis. Gastroenterology 2009;
116) Thia KT, Loftus EV, Pardi DS, et al. Inter-observer Agreement and the Use of Visual
Analogue Scale for Endoscopic Activity Assessment in Ulcerative Colitis. Gastroenterology 2009;
117) Pardi DS, Loftus EV, Tremaine WJ, Sandborn WJ. A Randomized, Double-Blind,
Placebo-Controlled Trial of Budesonide for the Treatment of Active Lymphocytic Colitis. Gastroenterology 2009;
118) Holubar SD, Cima RR, Sandborn WJ, Pardi DS. Treatment and Prevention of Pouchitis:
A Meta-analysis of Randomized Trials. Gastroenterology 2009; 119) Swoger JM, Loftus EV, Pardi DS, et al. Pre-operative infliximab exposure and the
occurrence of post-operative complications following proctocolectomy and IPAA for ulcerative colitis. Gastroenterology 2009;
120) Moscandrew M, Becker B, Sandborn WJ, Pardi DS, et al. Natalizumab Use in Clinical
Practice in Patients with Moderate to Severe Crohn’s Disease. Gastroenterology 2009;
121) *Aronson S, Kammer P, Pardi DS. Clostridium difficile infection: a community-based epidemiological study. Am J Gastroenterol 2008;103:S204.
122) *Aronson S, Kammer P, Pardi DS. Treatment of Clostridium difficile infection in a
community-based cohort. Am J Gastroenterol 2008;103:S407-8.
123) Shen B, Pardi DS, Bennett A, et al. An Open-labeled Study of the Efficacy and Tolerability of AST-120 in the Treatment of Active Pouchitis, UEGW 2008.
124) Psychogios A, Maddalena AA, Pardi D, Lindor NM, Lindor KD, Lazaridis KN. A novel
CYBB mutation causing X-linked chronic granulomatous disease in a family with primary biliary cirrhosis and granulomatous colitis. 2008 ASHG meeting.
125) Guimaraes LS, Fidler J, Fletcher JG…Pardi DS, et al. Is radiation from follow up CT
enterography justified for younger patients undergoing CTE? 2008 RSNA meeting.
126) Malireddy K, Larson D, Sandborn WJ, Loftus EV, Faubion WA, Pardi DS, et al. Risk factors for recurrence and the impact of post operative prophylaxis in ileal colonic Crohn’s Disease. Dis Colon Rectum 2008;51:50
127) Swoger JM, Loftus EV, Pardi DS, et al. Adalimumab for Crohn’s Disease in Clinical
Practice at an Academic Medical Center: the First 118 Patients. Gastroenterology 2008;134:A662.
128) *Abdalla AA, Faubion WA, Loftus EV, Smyrk TC, Cha SS, Kammer PP, Sandborn WJ,
Pardi DS. The natural history of microscopic colitis treated with corticosteroids. Gastroenterology 2008;134:A121.
129) Tremaine WJ, Timmons LJ, Harmsen WS, Zinsmeister AR, Pardi DS, et al. Proximal
Progression of Left-Sided Ulcerative Colitis: A Population Based Study. Gastroenterology 2008;134:A5.
130) Bruining DH, Siddiki HA, FletcherJG ... Pardi DS, et al. Clinical Benefit of CT
Enterography in Suspected or Established Crohn’s Disease: Impact on Patient Management and Physician Level of Confidence. Gastroenterology 2008;134:A20.
131) Shen B, Pardi D, Bennett A, Sherman K. A Pilot study of the Efficacy of AST-120 in the
Treatment of Active Pouchitis. Am J Gastroenterol 2007;S477.
132) Loftus EV, Hanson KA, Pardi DS, et al. Evaluation of the combination of fecal lactoferrin
and fecal anti-saccharomyces cerevisiae antibodies to detect active Crohn’s disease. Am J Gastroenterol 2007;S486.
133) *Evans PE, Pardi DS, Sandborn WJ, et al. Risk Factors for Pouchitis After Ileal Pouch-
Anal Anastomosis for Ulcerative Colitis or Indeterminate Colitis: a Population-Based Study. Am J Gastroenterol 2007;S489.
134) Sharma P, Saini S, Rubinstein J, Bernard L, Pardi D, et al. Knowledge of Hepatocellular
Carcinoma Surveillance Guidelines and Current Practices: Results of a National survey. Am J Gastroenterol 2007;S449.
135)
136) Hansel SL, DiBaise JK, Crowell MD, Pardi DS, Bouras E. Prevalence and Impact of
Musculoskeletal Injury Among Endoscopists: A Controlled Study. Gastrointest Endosc 2007;65(5 suppl S): AB104.
137) Saini SD, Sharma P, Rubenstein JH Pardi D, Bernard L, Schoenfeld P. Knowledge of
Colon Polyp Surveillance Guidelines and Current Practices Amongst Gastroenterologists Preparing for Certification or Re-Certification Examinations. Gastrointest Endosc 2007;65:AB361
138) *Evans PE, Pardi DS, Loftus EV, et al. Pouchitis and Pouch Dysfunction After IPAA for
Ulcerative Colitis or Indeterminate Colitis: a Population-Based Study. Gastroenterology 2007;
139) *Peloquin JM, Pardi DS, Sandborn WJ, et al. Exposure to Diagnostic Ionizing Radiation in
a Population-Based Cohort of Patients with Inflammatory Bowel Disease. Am J Gastroenterol 2006;101:S448-9.
140) *Limsui D, Pardi DS, Abraham SC, et al. Interobserver Variability in the Histologic
Diagnosis of Microscopic Colitis. Am J Gastroenterol 2006.
141) *Akram S, Pardi DS, Smyrk TC. Effect of Tamoxifen on Clinical Course of Sclerosing Mesenteritis. Gastroenterology 2006;130:A-322.
142) Tremaine WJ, Timmons LJ, Loftus EV, Pardi DS, et al. Age and the Risk of Failure of
Medical Therapy in Inflammatory Bowel Disease: A Case-Control Study. Gastroenterology 2006;130:A-146.
143) Akram S, Loftus EV,Tremaine WJ, Faubion WA, Pardi DS, et al. Determinants of
Progression of Indefinite or Low-Grade Dysplasia to Advanced Dysplasia in Ulcerative Colitis. Gastroenterology 2006;130:A-647.
144)
145) *Kammer P, Pardi DS. Epidemiology of microscopic colitis. Society of Clinical Research
Associates, September 2005.
146) *Oxentenko AS, Vierkant RA, Pardi DS, et al. Follow-up of positive colorectal cancer screening tests: data from the second NCCRT trainee survey. Am J Gastroenterol 2005;100:S386.
(b) (4)
(b) (4)
147) *Oxentenko AS, Vierkant RA, Pardi DS, et al. Recognition of Patients at increased risk for colorectal cancer: data from the second NCCRT trainee survey. Am J Gastroenterol 2005;100:S385.
148) *Akram S, Murray JA, Pardi DS, Abraham SC, Alexander GL, Schaffner JA. Adult
Autoimmune Enteropathy: Mayo Clinic Rochester Experience. Am J Gastroenterol 2005;100:S102.
149) *Ruff KC, Harewood GC, Pardi DS. Association of INR levels with rates of post-
polypectomy bleeding. Am J Gastroenterol 2005;100:S368.
150) Salfiti N, Loftus EV, Tremaine WJ, Pardi DS, et al. Clinical features and outcomes of CMV colitis or pouchitis in patients with IBD. Am J Gastroenterol 2005;100:S316.
151) *Limsui D, Pardi DS, et al. Symptomatic overlap between irritable bowel syndrome and
microscopic colitis. Gastroenterology 2005;128:A-331. AGA poster of Distinction.
152) *Boetticher NC, Pardi DS. Assessing the utility of inpatient stool cultures: beyond the three-day rule. Gastroenterology 2005;128:A-558.
153) Pardi DS, Kammer PP, Loftus EV, et al. Microscopic colitis is not associated with
appendectomy or cholecystectomy. Gastroenterology 2005;128;A-324.
154) Solem CA, Loftus EV, Fletcher JG, et al. Small Bowel Imaging in Crohn's Disease: A Prospective, Blinded, 4-Way Comparison Trial. Gastroenterology 2005;128:A-74.
155) Pardi DS, Loftus EV, Kammer PP, et al. Collagenous colitis, but not lymphocytic colitis, is
associated with cigarette smoking. Am J Gastroenterol 2004;99:S116.
156) Pardi DS, Kammer PP, Loftus EV, et al. Microscopic colitis is not associated with an increased risk of colorectal cancer. Am J Gastroenterol 2004;99:S115.
157) *Boetticher NC, Pardi DS, Loftus EV, Sandborn WJ. Clostridium difficile infection in ulcerative
colitis. Am J Gastroenterol 2004;99:S261.
158) *Chopra A, Loftus EV ,Tremaine WJ, et al. Budesonide in the treatment of inflammatory bowel disease: one year experience in clinical practice. Am J Gastroenterol 2004;99:S247.
159) *Oxentenko AS, Gores GJ, Lymp JF, Brown LS, Pardi DS. Factors predicting initial career
choices in GI fellows: differences in the trainee versus the training? Am J Gastroenterol 2004;99:S228. ACG Presidential Poster Award
160) Pardi DS, Smyrk TC, Kammer P, et al. The Epidemiology of Microscopic Colitis: A Population-
Based Study in Olmsted County, MN. Gastroenterology 2004;126:A124.
161) Pardi DS, Smyrk TC, Kammer P, Carpenter HA, Murray JA. Apoptotic colopathy: New Subtype of Microscopic Colitis or Epiphenomenon? Gastroenterology 2004;126:A253.
162) *Grisolano S, Ramage JI, Pardi DS, Petersen BT. Lower Gastrointestinal Bleeding Due to
Colonic Dieulafoy lesion: Incidence and Treatment Outcomes. GI Endoscopy 2004;
163) Oxentenko AS, Goel NK, Pardi DS, et al. “Barriers and Motivators of Colorectal Cancer Screening in Primary care Residents: Results of the NCCRT Survey. Gastroenterology 2004;126:A342.
164) Oxentenko AS, Goel NK, Pardi DS, et al. “Self-Assessed Priority Level of Common Preventive Health Services Relative to CRC Screening Among Primary Care Residents: Results of the NCCRT Survey. Gastroenterol 2004;126:A342.
165) Jacob EK, Kammer P, Pardi DS, et al. “Apoptotic colopathy” is an effect of oral sodium
phosphate bowel preparation solution. US and Canadian Academy of Pathology Annual Meeting, 2004.
166) Petersen W, Vierkant R, Goel N, Pardi D, et al. CRC screening education in primary care
training programs: data from the NCCRT Survey. Am Society of Preventive Oncology 28th annual meeting, Bethesda, MD, March 2004.
167) *Goel N, Pardi DS, Limburg PJ, et al. Perceived Adequacy of CRC Screening Education
Among Primary Care Residents: Results the NCCRT Survey, Am Society of Clinical Oncology GI Cancer meeting, San Francisco, CA, Jan 2004.
168) *Goel N, Pardi DS, et al. Concordance between Preferred and Actually Recommended CRC
Screening Options among Primary Care Residents: Results of the NCCRT Survey. AACR 2nd Annual Cancer Prevention Research meeting, Phoenix, Oct 2003. Cancer Epidemiol Biomark Prev 2003;12(Suppl):1279.
169) *Grisolano S, Pardi DS, Ramage JI, Petersen BT. Endoscopic complications occurring during
colonoscopy for acute lower GI hemorrhage, Am J Gastro, 2003;S285. 2003 ACG/Astra Zeneca Senior Fellow Award Recipient.
170) *Grisolano S, Pardi DS, Ramage JI, Petersen BT. Endoscopic hemoclip application in the
treatment of lower GI hemorrhage, Am J Gastro, 2003;S285.
171) *Akram S, Pardi DS, Smyrk TC. Sclerosing mesenteritis: The Mayo Clinic Experience. (Clinical features and tx response) Gastroenterology 2003;A-190.
172) *Grisolano S, Pardi DS, Petersen BT. Endoscopic stigmata predict risk of rebleeding in acute
lower GI bleeding. Gastrointest Endosc 2003;57:AB215.
173) Delgado-Aros S, Chial H, Ferber I, Szarka L, Pardi D, et al. The K-opioid agonist asimadoline decreases satiety and fasting colonic tone in humans. Gastroenterology 2002;122:A59.
174) Smoot R, Gostout CJ, Rajan E, Pardi DS, et al. Is early colonoscopy for acute diverticular
bleeding needed? Gastrointest Endosc 2002;55:AB123.
175) Kakar S, Pardi DS, Burgart LJ. Discrete colon ulcers accompanying collagenous colitis: implication of NSAIDs. Am J Gastroenterol 2001;96 suppl:S153.
176) Pardi DS, Ramnath VR, Loftus EV Jr, Tremaine WJ, Sandborn WJ. Treatment outcomes in
lymphocytic colitis. Gastroenterology 2001;118:A13.
177) Pardi DS, Loftus EV Jr, Kremers WK, Keach JC, Lindor KD. Ursodeoxycholic acid as a chemopreventative agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology 2001;118:A447.
178) *Schwartz DA, Pardi DS, Murray JA. The use of Montelukast as a steroid sparing agent for
recurrent eosinophilic gastroenteritis. Am J Gastroenterol 2000;96:2605.
179) *Decker GA, Pardi DS. Gastric outlet obstruction: an unusual complication of TB gastroduodenitis in two brothers. Am J Gastroenterol 2000;96:2596.
180) Pardi DS, Tremaine WJ, Sandborn WJ, Loftus EV. Use of immunomodulators in microscopic colitis. Gastroenterology 2000;116:A788.
181) Viramontes B, McKinzie S, Pardi DS, Burton D, Thomforde G, Camilleri M. Alosetron retards
small bowel and overall colonic transit in diarrhea-predominant irritable bowel syndrome. Gastroenterology 2000; 116:A848.
182) Pardi DS, Miller SM, Miller DL, Burgart LJ, Szurszewski JH, Lennon VA, Farrugia G. Loss of
Interstitial Cells of Cajal and Paraneoplastic Dysmotility. Am J Gastroenterol 1999;94:2726.
183) Pardi DS, Tremaine WJ, Sandborn WJ, Loftus EV, Poland GA, Melton LJ. Early infection with measles virus is associated with an increased risk of ulcerative colitis. Gastroenterology 1998;114:A1058.
184) Pardi DS, Tremaine WJ, Sandborn WJ, Loftus EV, Poland GA, Melton LJ, Zinsmeister AR.
Perinatal measles exposure is not invariably associated with the development of IBD. Am J Gastroenterol 1997;92:1684.
185) Pardi DS, Loftus EV, Tremaine WJ, Sandborn WJ, Alexander GL, Balm RK, Gostout CJ.
Acute major GI hemorrhage in inflammatory bowel disease. Gastrointest Endosc 1997;45:AB114.
186) Pardi DS, Leighton JA. Pneumatosis coli: a rare finding in Clostridium difficile-associated pseudomembranous colitis. Am J Gastroenterol 1996;91:2033.
187) Pardi DS, Douglas DD. Hepatitis-associated aplastic anemia: further evidence for Parvovirus
B19 as a causative agent. Am J Gastroenterol 1996;91:1953.
